Novel tetrahydropteridine derivative as well as synthesis method and application thereof

By optimizing the molecular structure of a novel tetrahydropteridine derivative, the problems of poor drug resistance and selectivity of Plk1 kinase inhibitors in tumor cells have been solved, achieving highly efficient inhibition of Plk1 kinase and improved pharmacokinetic properties, making it suitable for treating diseases caused by excessive proliferation of malignant tumor cells.

CN119019399APending Publication Date: 2024-11-26RUNYAO RENZHI (BEIJING) TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411289097.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-09-18
Filing Date
2024-09-13
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing Plk1 kinase inhibitors face challenges during development, including tumor cell resistance and poor selectivity for members of the same kinase family. Furthermore, the pharmacokinetic properties of these compounds limit their clinical application.

Method used

To develop a novel tetrahydropteridine derivative, by optimizing the molecular structure to improve the inhibitory activity and selectivity against Plk1 kinase and improve water solubility, providing the possibility of oral administration.

Benefits of technology

It improves the targeting of Plk1 kinase, reduces the impact on other targets, reduces adverse reactions, and enhances water solubility, thus making it possible to develop oral drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019399A_ABST
    Figure CN119019399A_ABST
Patent Text Reader

Abstract

The invention discloses a novel tetrahydropteridine derivative as well as a synthesis method and application thereof, the derivative is shown in a general formula (I), and the definition of substituent groups is shown in the specification. According to the present invention, the high Plk1 inhibition activity is maintained while the selectivity on the same family kinases (Plk2 and Plk3) and the whole kinase spectrum is improved so as to improve the Plk1 kinase targeting property, such that the effect of the drug on other target spots is reduced while the drug effect is performed at the action site, and the adverse reaction event is reduced. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to but is not limited to the field of pharmaceutical chemistry technology, in particular to a novel tetrahydropteridine derivative and a synthesis method thereof and its use as a Plk1 kinase inhibitor in medicine. Background Art

[0002] Protein kinases are important signaling molecules that can affect the cell signal transduction process. They can affect the function of proteins in various ways, and then affect the normal cycle of cells. The dysregulation of protein kinases is also related to the pathogenesis of many diseases. Therefore, protein kinases have become one of the most important drug targets in recent years. The Polo-like kinase family (Plks) belongs to a highly conserved serine / threonine kinase family. There are five members in this family, namely Plk1-5. Among them, Plk1 is abnormally active in the mitosis process of cells and tissues. Studies have shown that the overexpression of Plk1 is also closely related to the formation of many human cancers (such as leukemia, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, prostate cancer, etc.).

[0003] Specific Plk1 inhibitors can induce selective killing of cancer cells without affecting normal cells. So far, the reported specific Plk1 inhibitors mainly target the KD domain and PBD domain of Plk1. Among them, compounds with 5,6,7,8-tetrahydropteridine as the skeleton targeting the KD domain, such as BI 2536 and BI 6727, have shown good Plk1 kinase inhibition activity and anti-tumor cell proliferation activity. For example, the synthesis method of some tetrahydropteridine skeleton derivatives and their use as protein kinase inhibitors in the treatment of tumors and other diseases are disclosed in patents WO01 / 019825 and CN101652365.

[0004] Although there are still many specific Plk1 kinase inhibitors reported, some of them have good inhibitory activity. However, due to the constraints of compound pharmacokinetics and other aspects, only a few Plk1 inhibitors remain in the clinical research stage and have not yet been approved for marketing. The most important reason is the drug resistance to different types of tumor cells and the poor selectivity for other members of the same kinase family. Therefore, it is urgent to develop new Plk1 kinase inhibitors with high activity, high selectivity, low toxicity and side effects, and improved pharmacokinetics. Summary of the invention

[0005] The present application provides a novel tetrahydropteridine derivative, which improves its selectivity for Plk1 homologous kinases while maintaining its high inhibitory activity against Plk1. At the same time, compared with the reported representative drug BI 2536 of 5,6,7,8-tetrahydropteridine structure derivatives, the derivatives provided in the present application have improved physical and chemical properties such as water solubility, and provide the possibility for the development of oral drugs.

[0006] The present application provides a novel tetrahydropteridine derivative, wherein the derivative is represented by the general formula (I), or its tautomer, geometric isomer, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof:

[0007]

[0008] R1 and R2 are each independently selected from hydrogen and C1-C6 alkyl;

[0009] R3 is hydrogen, C1-C 10 Alkyl, C6-C 12 Aryl, C3-C 10 Cycloalkyl, or C2-C 12 Heterocycloalkyl, here, the C1-C 10 Alkyl, C6-C 12 Aryl, C3-C 10 Cycloalkyl, or C2-C 12 Heterocycloalkyl, optionally, substituted by one or more selected from hydroxy, nitro, halogen, C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, C6-C 12 Aryl-substituted C1-C6 alkyl, halogenated C1-C6 alkoxy, hydroxy-substituted C1-C6 alkyl, C6-C 12 Aryl, -C(O)-R 15 、-C(O)-OR 15 、-C(O)NR 15 R 16 、-NR 15 R 16 and -NC(O)R 15 Substituents, wherein R 15 and R 16 Each is independently selected from hydrogen and C1-C6 alkyl;

[0010] R4 is hydrogen or C1-C6 alkyl;

[0011] R5 is halogen, unsubstituted C1-C6 alkoxy or C1-C6 alkoxy substituted by hydroxy;

[0012] X is hydrogen or halogen;

[0013] L1 and L2 are each independently selected from a single bond (or absent) and C1-C4 alkylene optionally substituted by a group of Group A;

[0014] R 10 is hydrogen or a C1-C4 alkyl group optionally substituted by a group of Group A, or R 10 and R7 and together with the groups to which they are attached form a C2-C 11 Azacycloalkyl, or R 10 and R9 and together with the groups to which they are attached form a C2-C 11 Azacycloalkyl;

[0015] R6 and R7 are each independently selected from hydrogen, halogen, C1-C4 alkyl optionally substituted by a group of Group A, nitro, hydroxyl, and C1-C4 alkoxy optionally substituted by a group of Group A;

[0016] R8 and R9 are each independently selected from hydrogen, C1-C6 alkyl optionally substituted by a group of Group A, and C1-C4 alkanoyl optionally substituted by a group of Group A;

[0017] Group A groups are hydroxyl, nitro, halogen, C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, C6-C 12 Aryl-substituted C1-C6 alkyl, halogenated C1-C6 alkoxy or C6-C 12 Aryl.

[0018] In another aspect, the present application provides a method for preparing the novel tetrahydropteridine derivatives.

[0019] The third aspect of the present application provides a pharmaceutical composition, which comprises the compound of general formula (I) described in the present application, or its tautomers, geometric isomers, enantiomers, diastereomers, or mixtures thereof or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier excipient or diluent.

[0020] In a fourth aspect, the present application provides a compound of the general formula (I) described in the present application, or its tautomer, geometric isomer, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for use as a medicine, or for use as a selective inhibitor of Plk1 kinase.

[0021] In a fifth aspect, the present application provides the use of the compound of general formula (I) described in the present application, or its tautomers, geometric isomers, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for preparing drugs for treating or preventing diseases caused by excessive proliferation of malignant tumor cells.

[0022] The sixth aspect of the present application provides a method for treating or preventing diseases caused by excessive proliferation of malignant tumor cells, the method comprising administering the compound of general formula (I) described in the present application, or its tautomers, geometric isomers, enantiomers, diastereomers, or mixtures thereof, or its pharmaceutically acceptable salts, or the pharmaceutical composition to a patient in need thereof.

[0023] In an embodiment of the first aspect, the present application provides a novel tetrahydropteridine derivative as shown in the general formula (I), or its tautomer, geometric isomer, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof:

[0024]

[0025] R1 and R2 are each independently selected from hydrogen and C1-C6 alkyl; preferably, R1 is hydrogen and R2 is C1-C6 alkyl; here, the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl or n-hexyl, etc.;

[0026] R3 is hydrogen, C1-C 10 Alkyl, C6-C 12 Aryl, C3-C 10 Cycloalkyl, or C2-C 12 Heterocycloalkyl, here, the C1-C 10 Alkyl, C6-C 12 Aryl, C3-C 10 Cycloalkyl, or C2-C 12 Heterocycloalkyl, optionally, substituted by one or more selected from hydroxy, nitro, halogen, C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, C6-C 12 Aryl-substituted C1-C6 alkyl, halogenated C1-C6 alkoxy, hydroxy-substituted C1-C6 alkyl, C6-C 12 Aryl, -C(O)-R 15 、-C(O)-OR 15 、-C(O)NR 15 R 16 、-NR 15 R 16 and -NC(O)R 15 Substituents, wherein R 15 and R 16 Each is independently selected from hydrogen and C1-C6 alkyl; preferably, R3 is C1-C 10 Alkyl, C3-C 10 Cycloalkyl, or C2-C 12Heterocycloalkyl; Here, the C1-C 10 The alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl or n-decyl; the C6-C 12 Aryl is phenyl, naphthyl or indenyl; the C3-C 10 The cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, cyclononyl or cyclodecyl; 12 The heterocycloalkyl group is oxirane, oxetanyl, dioxolanyl, dithiacyclopentyl, dioxanyl, aziridinyl, azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, dihydrooxazolyl, tetrahydrooxazolyl, tetrahydrothiazolyl, tetrahydroisoquinolyl, octahydroisoquinolyl, decahydroisoquinolyl, tetrahydroquinolyl, octahydroquinolyl, tetrahydroimidazolinyl, pyrazolidinyl, pyrrolidinyl, pyrrolidinone, piperidinyl, piperidone, piperazinyl, piperazinone, N-methylpyrrolidinyl, 2- hydroxymethylpyrrolidinyl, 3-hydroxypyrrolidinyl, N-methylpiperazinyl, N-benzylpiperazinyl, N-acetylpiperazinyl, N-methylsulfonylpiperazinyl, 4-hydroxypiperidinyl, 4-aminocarbonylpiperidinyl, 2-hydroxyethylpiperidinyl, 4-hydroxymethylpiperidinyl, imidazolidinyl, tetrahydroimidazolonyl, morpholinyl, thiomorpholinyl, 1,1-dioxothiomorpholinyl, quinuclidinyl or nortropine, or a ring of the above which is benzo-fused, such as, for example, benzopyrrolidinyl, benzomorpholinyl, etc.;

[0027] R4 is hydrogen or C1-C6 alkyl; preferably, R4 is C1-C6 alkyl; here, the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl or n-hexyl;

[0028] R5 is halogen, unsubstituted C1-C6 alkoxy or C1-C6 alkoxy substituted by hydroxy; preferably, R5 is unsubstituted C1-C6 alkoxy or C1-C6 alkoxy substituted by hydroxy; here, the halogen is fluorine, chlorine, bromine or iodine; the unsubstituted C1-C6 alkoxy is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy or n-hexoxy; the C1-C6 alkoxy substituted by hydroxy means that any position on the alkyl group is substituted by hydroxy, including but not limited to hydroxymethoxy, hydroxyethoxy, hydroxy-n-propoxy, hydroxyisopropoxy, hydroxy-n-butoxy, hydroxyisobutoxy, hydroxy-sec-butoxy, hydroxy-tert-butoxy, hydroxy-n-pentoxy or hydroxy-n-hexoxy;

[0029] X is hydrogen or halogen; here, the halogen is chlorine, bromine or fluorine;

[0030] L1 and L2 are each independently selected from a single bond (or absent) and a C1-C4 alkylene group optionally substituted by a group of Group A; Here, the C1-C4 alkylene group is -CH2-, -CH2-CH2-, -CH(CH3)-CH2-, -CH2-CH(CH3)-, -CH2-CH2-CH2- or -CH2-CH2-CH2-CH2-;

[0031] R 10 is hydrogen or a C1-C4 alkyl group optionally substituted by a group of Group A, or R 10 and R7 and together with the groups to which they are attached form a C2-C 11 Azacycloalkyl, or R 10 and R9 and together with the groups to which they are attached form a C2-C 11 Here, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl; the C2-C 11 The aziridine group is aziridinyl, azetidinyl, pyrazolidinyl, pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, tetrahydroimidazolonyl, morpholinyl, thiomorpholinyl or 1,1-dioxothiomorpholinyl;

[0032] R6 and R7 are each independently selected from hydrogen, halogen, C1-C4 alkyl optionally substituted by a group of Group A, nitro, hydroxyl and C1-C4 alkoxy optionally substituted by a group of Group A; Here, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl; Here, the C1-C4 alkoxy is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy;

[0033] R8 and R9 are each independently selected from hydrogen, C1-C6 alkyl optionally substituted by a group of Group A, and C1-C4 alkanoyl optionally substituted by a group of Group A; wherein the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl or n-hexyl; and the C1-C4 alkanoyl is formyl, acetyl, propionyl or butyryl;

[0034] Group A groups are hydroxyl, nitro, halogen, C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, C6-C 12 Aryl-substituted C1-C6 alkyl (e.g., benzyl), halogenated C1-C6 alkoxy or C6-C 12 Aryl.

[0035] In some embodiments of the first aspect, the present application provides a novel tetrahydropteridine derivative as shown in the general formula (I), wherein R1 is hydrogen and R2 is ethyl, and the carbon atom to which R1 and R2 are attached is in R configuration.

[0036] In some embodiments of the first aspect, the present application provides a novel tetrahydropteridine derivative as shown in the general formula (I), wherein R3 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl or piperazinyl, preferably, R3 is isopropyl, cyclopentyl, pyrrolidinyl or piperazinyl.

[0037] In some embodiments of the first aspect, the present application provides a novel tetrahydropteridine derivative as shown in the general formula (I), wherein R4 is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl or tert-butyl, preferably, R4 is methyl.

[0038] In some embodiments of the first aspect, the present application provides a novel tetrahydropteridine derivative as shown in the general formula (I), wherein R1 is hydrogen and R2 is ethyl, and the carbon atom to which R1 and R2 are attached is in R configuration; R3 is isopropyl, cyclopentyl, pyrrolidinyl or piperazinyl; and R4 is methyl.

[0039] In some embodiments of the first aspect, the present application provides a novel tetrahydropteridine derivative as shown in the general formula (I), wherein R5 is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, hydroxymethoxy, hydroxyethoxy, hydroxy-n-propoxy, hydroxyisopropoxy, hydroxy-n-butoxy, hydroxyisobutoxy, hydroxy-sec-butoxy or hydroxy-tert-butoxy, preferably, R5 is methoxy, 2-hydroxyethoxy, 3-hydroxypropoxy or 2-hydroxypropoxy.

[0040] In some embodiments of the first aspect, the present application provides a novel tetrahydropteridine derivative as shown in the general formula (I), wherein X is hydrogen, chlorine, bromine, fluorine or iodine, preferably, X is hydrogen, chlorine or fluorine.

[0041] In some embodiments of the first aspect, the present application provides a novel tetrahydropteridine derivative as shown in the general formula (I), wherein R1 is hydrogen and R2 is ethyl, and the carbon atom to which R1 and R2 are attached is in R configuration; R3 is isopropyl, cyclopentyl, pyrrolidinyl or piperazinyl; R4 is methyl; R5 is methoxy, 2-hydroxyethoxy, 3-hydroxypropoxy or 2-hydroxypropoxy; and X is hydrogen, chlorine or fluorine.

[0042] In some embodiments of the first aspect, the present application provides a novel tetrahydropteridine derivative as shown in general formula (I), wherein: for

[0043] In some embodiments of the first aspect, the present application provides a novel tetrahydropteridine derivative as shown in general formula (I), wherein: for

[0044] In some embodiments of the first aspect, the present application provides a novel tetrahydropteridine derivative as shown in general formula (I), wherein: Medium R 10 is hydrogen, L1 is a single bond, -CH2- or -CH2-CH2-; L2 is a single bond, -CH2- or -CH2-CH2-; R6 and R7 are both hydrogen; R8 and R9 are each independently selected from hydrogen, C1-C6 alkyl optionally substituted by a group of Group A, and C1-C4 alkanoyl optionally substituted by a group of Group A; preferably, R 10 is hydrogen, L1 is -CH2-; L2 is -CH2-; R6 and R7 are both hydrogen; R8 is hydrogen, and R9 is methyl or ethyl; More preferably, R 10 is hydrogen, L1 is -CH2-; L2 is -CH2-; R6 and R7 are both hydrogen; R8 is hydrogen, and R9 is ethyl.

[0045] In some embodiments of the first aspect, the present application provides a novel tetrahydropteridine derivative as shown in general formula (I), wherein: It is R8(R9)N-pyrrolidinyl optionally substituted by a group of Group A or R8(R9)N-piperidinyl optionally substituted by a group of Group A, and R8 and R9 are each independently selected from hydrogen, C1-C6 alkyl optionally substituted by a group of Group A, and C1-C4 alkanoyl optionally substituted by a group of Group A; preferably, it is R8(R9)N-pyrrolidinyl or R8(R9)N-piperidinyl, and R8 and R9 are each independently selected from hydrogen and tert-butoxycarbonyl; more preferably, it is 4-aminopiperidine or 4-tert-butoxycarbonyl-aminopiperidine.

[0046] In some embodiments of the first aspect, the present application provides a novel tetrahydropteridine derivative as shown in general formula (I), wherein: It is 4-R8-piperazinyl optionally substituted by a group of Group A, R8 is hydrogen, C1-C6 alkyl optionally substituted by a group of Group A, or C1-C4 alkanoyl optionally substituted by a group of Group A; preferably, it is 4-R8-piperazinyl, R8 is hydrogen, methyl, ethyl or tert-butoxycarbonyl.

[0047] In some embodiments of the first aspect, the present application provides the following compounds, or pharmaceutically acceptable salts thereof:

[0048]

[0049]

[0050] In the embodiment of the present application, the compound provided by the present application is obtained in the form of a free form or a pharmaceutically acceptable salt thereof. The term "pharmaceutically acceptable salt" refers to a salt that retains the biological effectiveness and characteristics of the compound of the present application, and does not generally refer to a salt that is biologically or otherwise undesirable. In many cases, due to the presence of an amino and / or carboxyl group or a group similar thereto, the compound of the present application can form an acid salt and / or a base salt.

[0051] The compounds of the present application can form pharmaceutically acceptable acid addition salts with inorganic acids and organic acids. The inorganic acids include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. The organic acids include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, etc.

[0052] In some embodiments of the present application, the present application provides the following forms of the novel tetrahydropteridine derivatives: acetate, ascorbate, adipate, aspartate, benzoate, benzenesulfonate, bromide / hydrobromide, bicarbonate / carbonate, bisulfate / sulfate, camphorsulfonate, decanoate, chloride / hydrochloride, chlorophylline, citrate, edisylate, fumarate, glucuronate, gluconate, glutamate, glutarate, glycolate, hippurate, hydroiodide / iodide, isethionate The invention can be in the form of a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate, a bisphosphonate

[0053] The novel tetrahydropteridine derivatives provided in the present application include compounds having formula (I), compounds having subformulas thereof and exemplary compounds, pharmaceutically acceptable salts thereof, and all stereoisomers (including diastereomers and enantiomers), geometric isomers (E or Z), tautomers, and isotope-labeled compounds (including deuterium substitutions), and solvates or hydrates thereof.

[0054] The present application includes all possible stereoisomers, including racemic mixtures, diastereomeric mixtures and optically pure forms.Optically active (R)- and (S)-stereoisomers may be prepared by chiral synthesis or using chiral reagents, or resolved using conventional techniques.

[0055] Any asymmetric atom (e.g., carbon, etc.) of one or more compounds of the present application can exist in a racemic or enantiomerically enriched form, for example, (R)-, (S)-, or (R, S)-configuration. In some embodiments, each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess of (R)- or (S)-configuration.

[0056] In an embodiment of the second aspect, the present application provides a method for preparing a novel tetrahydropteridine derivative as shown in general formula (I), the preparation method comprising:

[0057]

[0058] Formula (II) and formula (III) are coupled to obtain a novel tetrahydropteridine derivative as shown in general formula (I), wherein the definitions of the substituents in formula (II) and formula (III) are the same as those in formula (I).

[0059] In some embodiments of the second aspect, the coupling reaction uses an anhydrous polar aprotic solvent, in the presence of a Pd metal catalyst such as palladium acetate, palladium trifluoroacetate, tri(dibenzylideneacetone) dipalladium or bis(dibenzylideneacetone) palladium, 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene, 2-dicyclohexylphosphino-2'-(N,N-dimethylamine)-biphenyl and the like are added, and the aromatic amine represented by formula (II) and the aromatic halide represented by formula (III) are metal coupled under an inert gas atmosphere under alkaline conditions of 80°C-150°C, and the reaction time is 12-24 hours to obtain the product; optionally, the coupling reaction further includes the step of removing the hydroxyl or amino protecting group, for example, a hydrolysis reaction is carried out under alkaline conditions to obtain the product.

[0060] In some embodiments of the second aspect, the anhydrous polar aprotic solvent is 1,4-dioxane, acetonitrile or N,N-dimethylformamide; the Pd metal catalyst is palladium acetate, palladium trifluoroacetate, tris(dibenzylideneacetone)dipalladium or bis(dibenzylideneacetone)palladium; the ligand is 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene, 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)-biphenyl or dicyclohexyl[3,6- dimethoxy-2',4',6'-triisopropyl[1,1'-biphenyl]-2-yl]phosphine; the inert gas is argon or nitrogen; the alkaline condition is provided by inorganic bases such as sodium carbonate, potassium carbonate or cesium carbonate; the coupling reaction temperature is 80°C-150°C; the coupling reaction time is 12-24 hours; the molar ratio of the compound to the metal Pd catalyst, the ligand and the base is 1:0.02-0.1:0.2-1:1.5-2.

[0061] In some embodiments of the second aspect, the alkaline conditions of the deprotection reaction are provided by potassium carbonate; the hydrolysis reaction solvent is a mixed solvent of any one of methanol, ethanol or isopropanol and water; the hydrolysis reaction temperature is 25°C-60°C; the hydrolysis reaction time is 4-12 hours; the molar ratio of the compound to the base is 1:2-5; and the mixing ratio between the alcohol solvent and water is 5:3.

[0062] In the third aspect of the present application, the present application provides a pharmaceutical composition, which comprises a therapeutically effective amount of the above-mentioned novel tetrahydropteridine derivative, or its tautomer, geometric isomer, enantiomer, diastereomer, or a mixture thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier excipient or diluent.

[0063] In the embodiment of the third aspect, the pharmaceutical composition of the present application can be formulated for specific administration routes, such as oral administration, parenteral administration (such as by injection, instillation, transdermal or topical administration) and rectal administration. Topical administration also includes suction or intranasal administration. The pharmaceutical composition of the present application can be made into solid form (including but not limited to capsules, tablets, pills, granules, powders or suppositories) or liquid form (including but not limited to solutions, suspensions or emulsions). Tablets can add film coatings or enteric coatings according to methods known in the art. Typically, the pharmaceutical composition is a tablet or gelatin capsule comprising an active ingredient and one or more of the following excipients: a) diluents, such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine; b) lubricants, such as silicon dioxide, talc, stearic acid and its magnesium or calcium salts, and / or polyethylene glycol; c) binders, such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidone; d) disintegrating agents, such as starch, agar, alginic acid or its sodium salt, or effervescent mixtures; and e) absorbents, colorants, flavorings and sweeteners. Those skilled in the art can refer to, for example, Remington The Science and Practice of Pharmacy, 22nd edition, Pharmaceutical Press 2013.

[0064] The fourth aspect of the present application provides a compound of the general formula (I) described in the present application, or its tautomer, geometric isomer, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for use as a medicine.

[0065] In an embodiment of the fourth aspect, the use for medicine may be use for use as a Plk1 kinase selective inhibitor. In some embodiments, the use is for use as a medicine for treating or preventing diseases caused by excessive proliferation of malignant tumor cells.

[0066] In a fifth aspect, the present application provides the use of the compound of general formula (I) described in the present application, or its tautomers, geometric isomers, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for preparing drugs for treating or preventing diseases caused by excessive proliferation of malignant tumor cells.

[0067] The sixth aspect of the present application provides a method for treating or preventing diseases caused by excessive proliferation of malignant tumor cells, the method comprising administering to a subject in need thereof a compound of the general formula (I) described in the present application, or its tautomers, geometric isomers, enantiomers, diastereomers, or a mixture thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described in the present application.

[0068] In the embodiments of the present application, the diseases caused by excessive proliferation of malignant tumors include: colorectal adenocarcinoma, pancreatic cancer, non-small cell lung cancer, small cell lung cancer, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, prostate cancer, epidermal cell carcinoma, esophageal cancer, thyroid cancer, acute leukemia, chronic myeloid leukemia, gastrointestinal cancer, liver cancer, lymphoma, myeloma, head and neck tumors, etc.

[0069] The novel tetrahydropteridine derivative provided in the present application has a simple synthesis method, and shows strong kinase inhibitory activity against Plk1 kinase in the kinase activity test results, and has good selectivity for Plk2 and Plk3 kinases in the same kinase family, thereby improving its targeting to Plk1 kinase, so that it can exert its efficacy at the site of action while reducing the impact of the drug on other targets and reducing the occurrence of adverse reactions. At the same time, the present application improves the water solubility and other physical and chemical properties of the reported 5,6,7,8-tetrahydropteridine structure derivative representative drug BI 2536, etc., providing the possibility for the development of oral drugs.

[0070] Other features and advantages of the present application will be described in the following description, and partly become apparent from the description, or be understood by implementing the present application. Other advantages of the present application can be realized and obtained by the schemes described in the description.

[0071] the term

[0072] As used herein, the term "subject" refers to mammals, primates (e.g., humans (male or female)), dogs, rabbits, guinea pigs, pigs, rats, and mice. In certain embodiments, the subject is a primate. In other embodiments, the subject is a human.

[0073] As used herein, the term "treatment" or "treating" of any disease or disorder refers to alleviating or ameliorating the disease or disorder (i.e., slowing or arresting the progression of the disease or at least one clinical symptom thereof); or alleviating or ameliorating at least one physical parameter or biomarker associated with the disease or disorder, including physical parameters or biomarkers that may not be discernible by the subject.

[0074] As used herein, the term "prevention" of any disease or disorder refers to prophylactic treatment of the disease or disorder; or delaying the onset or progression of the disease or disorder.

[0075] As used herein, a subject is "in need of" a treatment if the subject would benefit biologically, medically, or in quality of life from the treatment.

[0076] As used herein, the term "therapeutically effective amount" of a compound of the present application refers to the amount of the compound of the present application that will induce a biological or medical response in a subject (e.g., reduction or inhibition of enzyme or protein activity, or improvement of symptoms, alleviation of symptoms, slowing or delaying disease progression, or prevention of disease, etc.). BRIEF DESCRIPTION OF THE DRAWINGS

[0077] The accompanying drawings are used to provide an understanding of the technical solution of the present application and constitute a part of the specification. Together with the embodiments of the present application, they are used to explain the technical solution of the present application and do not constitute a limitation on the technical solution of the present application.

[0078] Figure 1 The therapeutic effect of compound 7 of the present application on a non-small cell lung cancer (A549) transplanted tumor mouse model; Figure 1 A in the middle shows the weight changes of mice; Figure 1 Middle B shows the change in A549 tumor volume; Figure 1 Middle C is the A549 tumor weight;

[0079] Figure 2 The therapeutic effect of compound 28 of the present application on a non-small cell lung cancer (K562) transplanted tumor mouse model; Figure 2 A in the middle is the tumor tissue removed at the end of the experiment; Figure 2 Middle B shows the change in A549 tumor volume; Figure 2 Middle C shows the weight changes of mice; Figure 2 D in the middle is the area of ​​tumor tissue peeled off from A549; Figure 2 Middle E is the weight of tumor tissue removed from A549. DETAILED DESCRIPTION

[0080] The technical solutions in the embodiments of the present application are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present application.

[0081] In all embodiments of the present application, the structures of the compounds were determined by nuclear magnetic resonance ( 1 H NMR) and mass spectrometry (MS). 1 The HNMR spectrum was measured using a nuclear magnetic resonance instrument (600 MHz, Agilent Technologies, USA, VNMRS600). The chemical shift is expressed in ppm, using tetramethylsilane as the internal standard (0.00 ppm). The measurement solvents were deuterated chloroform and deuterated dimethyl sulfoxide. 1H NMR notation: S = singlet, d = doublet, t = triplet, m = multiplet, br = broadened, dd = doublet of a doublet, dt = doublet of a triplet. Coupling constants, when given, are given in Hz.

[0082] The mass spectrum was measured using an LC / MS instrument (ACQUITY UPLC LCT Premier XE, Waters, USA), and the ionization method could be ESI or APCI.

[0083] The thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The silica gel plate used in thin layer chromatography (TLC) uses a specification of 0.15mm-0.2mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm-0.5mm. Column chromatography uses Yantai Huanghai silica gel 200-300 mesh silica gel as a carrier.

[0084] Kinases and cancer cell IC 50 The determination was carried out using NovoStar microplate reader (BMG, Germany).

[0085] The starting materials of this application were purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd., Aladdin Reagent Co., Ltd., Shanghai McLean Biochemical Technology Co., Ltd., Sinopharm Group Chemical Reagent Co., Ltd. and other companies.

[0086] Nitrogen atmosphere means that the reaction device is connected to a balloon with a volume of about 1L, and the gas in the original reaction device is replaced with nitrogen more than three times.

[0087] abbreviation

[0088] DMF: dimethylformamide; DMSO: dimethyl sulfoxide; ATP: adenosine triphosphate; MOPS: 3-(N-morpholino)propanesulfonic acid; EDTA: ethylenediaminetetraacetic acid; DTT: dithiothreitol; PBS buffer solution: phosphate buffered saline.

[0089] Example 1

[0090] The synthesis of (R)-8-cyclopentyl-7-ethyl-2-((2-(2-hydroxyethoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 1) is as follows:

[0091]

[0092] (1) Synthesis of intermediate (R)-2-aminobutyric acid methyl ester (intermediate 1b)

[0093] Step I: Dissolve the commercially available raw material 1a (10 g, 96.97 mmol) in 120 mL of CH3OH, and slowly add SOCl2 (15 mL, 0.21 mmol) into the system at 0°C using a constant pressure separatory funnel. After the addition of SOCl2 is complete, remove the ice bath and the constant pressure separatory funnel, stir at room temperature for about 15 minutes, and then place the apparatus in a 60°C oil bath for reflux reaction for 2 h. Concentrate the reaction solution under reduced pressure, add 80 mL of petroleum ether for repeated washing, and filter to obtain a pure white solid, which is dried in a vacuum oven overnight to obtain intermediate 1b (10.3 g, pure white solid, yield 91%).

[0094] (2) Synthesis of intermediate (R)-2-(cyclopentylamino)butyric acid methyl ester (intermediate 1c)

[0095] Step II: Add an appropriate amount of dichloromethane to a reaction vessel containing intermediate 1b (10.3 g, 55.60 mmol). At 0°C, observe the pH value of the reaction system first. If the reaction system is alkaline, add triethylamine dropwise to the reaction system until the system is weakly acidic (pH = 5-6). At this time, add cyclopentanone (5.14 mL, 58.37 mmol) in batches. After the reaction system is stable and does not release heat, remove the ice bath, stir and react at room temperature for 5 h, finally add sodium triacetoxyborohydride (16.76 g, 83.40 mmol) to the system, stir and react at room temperature for 18 h, and monitor the reaction at any time by fumigating the thin layer chromatography plate in an iodine cylinder to observe the changes in the raw material point and the product point. After the reaction of the raw materials was completed, the reaction was stopped and the reaction solution was neutralized with a saturated sodium bicarbonate aqueous solution. A large number of bubbles were generated after ultrasonication. After the bubbles disappeared, the reaction solution was extracted with dichloromethane and water (100 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 1c (15.6 g, light brown oil, yield 96%).

[0096] (3) Synthesis of intermediate (R)-methyl 2-((2-chloro-5-nitropyrimidin-4-yl)(cyclopentyl)amino)butanoate (Intermediate 1d)

[0097] Step III: Under ice bath conditions, take the intermediate 1c (15.6 g, 84.41 mmol) and dissolve it in an appropriate amount of 1,2-dichloroethane, then add sodium bicarbonate (28.4 g, 337.64 mmol) to the reaction system, and finally add 2,4-dichloro-5-nitropyrimidine (13.1 g, 67.53 mmol), and reflux in an oil bath at 60°C for 18 hours. After the raw materials are consumed, stop the reaction, first filter to remove the salt produced in the reaction, then extract with ethyl acetate and water (100 mL×3), combine the organic phases, dry over anhydrous sodium sulfate, and concentrate under reduced pressure. Finally, column chromatography (petroleum ether: ethyl acetate = 15:1) is used to obtain the intermediate 1d (15.9 g, yellow oil, yield 55%).

[0098] (4) Synthesis of Intermediate (R)-2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydropteridin-6(5H)-one (Intermediate 1e)

[0099] Step IV: Dissolve the intermediate 1d (15.9 g, 46.39 mmol) in an appropriate amount of glacial acetic acid solvent, add reduced iron powder (13.0 g, 231.95 mmol) to the reaction system in batches, and reflux in an oil bath at 60°C for 2 h. Monitor the progress of the reaction by TLC, and stop the reaction when the raw materials are consumed. First, filter with diatomaceous earth, collect the filtrate, and extract the filtrate with ethyl acetate and water (100 mL×3), combine the organic phases, dry over anhydrous sodium sulfate, and concentrate under reduced pressure. Finally, column chromatography (petroleum ether: ethyl acetate = 2:1) is used to obtain the intermediate 1e (9.4 g, light yellow solid, yield 72%).

[0100] (5) Synthesis of Intermediate (R)-2-chloro-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Intermediate 1f)

[0101] Step V: Dissolve the intermediate 1e (9.4 g, 33.40 mmol) in an appropriate amount of acetone, add anhydrous potassium carbonate (9.2 g, 66.80 mmol) and iodomethane (2.3 mL, 36.74 mmol), and reflux in an oil bath at 60°C for 4.5 h. Monitor the progress of the reaction by TLC, and stop the reaction when the raw materials are consumed. Extract the reaction solution with ethyl acetate and water (100 mL × 3), combine the organic phases, dry over anhydrous sodium sulfate, and concentrate under reduced pressure. Finally, column chromatography (petroleum ether: ethyl acetate = 2:1) is used to obtain the intermediate 1f (1.6 g, light yellow solid, yield 82%).

[0102] (6) Synthesis of Intermediate 2-(4-bromo-2-nitrophenoxy)ethane-1-ol (Intermediate 1h)

[0103] Step VI: Weigh the raw material 4-bromo-2-nitrophenol (1.6 g, 7.34 mmol) into a thick-walled pressure bottle and dissolve it in a small amount of DMF solvent, add 2-bromoethanol (1.11 mL, 18.13 mmol) to the reaction system, then add N,N-diisopropylethylamine (5.75 mL, 33.03 mmol) dropwise to the reaction system, and stir the reaction at 120°C for 3 h. After the reaction is completed, extract with water and ethyl acetate (100 mL×3), combine the organic phases, dry over anhydrous sodium sulfate, concentrate under reduced pressure, and finally obtain intermediate 1h (1.6 g, orange-yellow solid, yield 85%) by column chromatography (petroleum ether: ethyl acetate = 6:1).

[0104] (7) Synthesis of Intermediate 2-(4-bromo-2-nitrophenoxy)ethyl acetate (Intermediate 1i)

[0105] Step VII: 1h (1.6 g, 6.15 mmol) was dissolved in dichloromethane, and 4-dimethylaminopyridine (1.2 g, 9.84 mmol) and acetic anhydride (0.615 mL, 3.47 mmol) were added to the reaction system under ice bath conditions. After the system was stable, the ice bath was removed and the reaction was stirred at room temperature for 5 h. After the reaction was completed, the volatile solvent in the system was dried by spin drying, and the mixture was extracted with water and ethyl acetate (100 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and finally column chromatography (petroleum ether: ethyl acetate = 8:1) was used to obtain intermediate 1i (1.7 g, yellow-green oil, yield 91%).

[0106] (8) Synthesis of Intermediate 2-(4-(4-methylpiperazin-1-yl)-2-nitrophenoxy)ethyl acetate (Intermediate 1j)

[0107] Step VIII: 1i (1.7 g, 5.59 mmol) was dissolved in 10 mL of anhydrous 1,4-dioxane, and 1-methylpiperazine (0.63 mL, 5.65 mmol), cesium carbonate (2.73 g, 8.385 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.65 g, 1.12 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.51 g, 0.559 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 115°C for 18 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with water and ethyl acetate (100 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 1j (1.46 g, brown oil, yield 81%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0108] (9) Synthesis of Intermediate 2-(2-amino-4-(4-methylpiperazin-1-yl)phenoxy)ethyl acetate (Intermediate 1k)

[0109] Step IX: 1j (1.46 g, 4.98 mmol) was dissolved in a mixture of ethanol and water (volume ratio of 2:1) as a solvent, ammonium chloride (0.8 g, 14.94 mmol) was added, and reduced iron powder (1.39 g, 24.9 mmol) was slowly added, and the mixture was refluxed and stirred at 60°C for 2 hours. After the reaction was completed, diatomaceous earth was used for suction filtration, and the filtrate was collected. The filtrate was extracted with ethyl acetate and water (100 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, the intermediate 1k (0.73 g, brown-yellow solid, yield 55%) was obtained by column chromatography (ethyl acetate: methanol = 8:1).

[0110] (10) Synthesis of Intermediate (R)-2-(2-((4-cyclopentyl-3-ethyl-1-methyl-2-oxo-1,2,3,4-tetrahydropteridin-6-yl)amino)-4-(4-methylpiperazin-1-yl)phenoxy)ethyl acetate (Intermediate 11)

[0111] Step X: 1k (0.73 g, 2.48 mmol) was dissolved in anhydrous 1,4-dioxane, and intermediate 1f (0.88 g, 2.98 mmol), cesium carbonate (1.21 g, 3.72 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.29 g, 0.5 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.23 g, 0.25 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 110°C for 16 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with ethyl acetate and water. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 1l (0.9 g, brown solid, yield 61%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0112] (11) Synthesis of the target product (R)-8-cyclopentyl-7-ethyl-2-((2-(2-hydroxyethoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 1)

[0113] Step XI: 11 (0.9 g, 1.51 mmol) was dissolved in a mixture of methanol and water (volume ratio of 5:3) as a solvent, and then potassium carbonate (0.62 g, 4.53 mmol) was added to the reaction system and stirred at room temperature for 5 hours. After the reaction was completed, the volatile solvent was removed by concentration under reduced pressure, and compound 1 (422 mg, light yellow solid, yield 55%) was obtained by column chromatography (petroleum ether: ethyl acetate = 6:1); 1 H NMR (600MHz, DMSO-d6) δ (ppm): 8.09 (d, J = 48.3Hz, 1H), 7.86 (d, J = 13.2Hz, 2H), 6.91 (d, J = 8.3Hz, 1H), 6.4 9(dd,J=8.7,2.5Hz,1H),5.11(s,1H),4.56(dd,J=16.4,8.2Hz,1H),4.21(dt,J=19.4,9.7Hz,1H),4.01(t, J=4.3Hz,2H),3.81-3.70(m,2H),3.29(s,4H),3.06(s,4H),2.50(s,4H),2.26(s,3H),2.06-1.99(m,1H),1 .96(d,J=10.2Hz,1H),1.87-1.68(m,5H),1.67-1.56(m,3H),0.82(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 510.3197.

[0114] Example 2

[0115] Synthesis of (R)-8-cyclopentyl-7-ethyl-2-((2-(2-hydroxyethoxy)-5-(piperazin-1-yl)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 2), the reaction route is as follows:

[0116]

[0117] (1) Synthesis of Intermediate 2-(2-nitro-4-(piperazin-1-yl)phenoxy)ethyl acetate (Intermediate 2j)

[0118] Step I: 1i (1.7 g, 5.59 mmol) was dissolved in 10 mL of anhydrous 1,4-dioxane, and piperazine (0.64 mL, 6.71 mmol), cesium carbonate (2.73 g, 8.385 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.65 g, 1.12 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was pumped out several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.51 g, 0.559 mmol) was quickly added, and the nitrogen was repeatedly pumped out with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 90°C for 18 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with water and ethyl acetate (100 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 2j (1.26 g, brown oil, yield 73%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0119] (2) Synthesis of Intermediate 2-(2-amino-4-(piperazin-1-yl)phenoxy)ethyl acetate (Intermediate 2k)

[0120] Step II: 2j (1.26 g, 4.07 mmol) was dissolved in a mixture of ethanol and water (volume ratio of 2:1) as a solvent, ammonium chloride (0.65 g, 12.21 mmol) was added, and then reduced iron powder (1.14 g, 20.35 mmol) was slowly added. The mixture was stirred under reflux at 60°C for 2 hours. After the reaction was completed, diatomaceous earth was used for suction filtration, and the filtrate was collected. The filtrate was extracted with ethyl acetate and water (100 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, the intermediate 2k (0.67 g, yellow solid, yield 59%) was obtained by column chromatography (ethyl acetate: methanol = 8:1).

[0121] (3) Synthesis of Intermediate (R)-2-(2-((4-cyclopentyl-3-ethyl-1-methyl-2-oxo-1,2,3,4-tetrahydropteridin-6-yl)amino)-4-(piperazin-1-yl)phenoxy)ethyl acetate (Intermediate 21)

[0122] Step III: 2k (0.67 g, 2.40 mmol) was dissolved in anhydrous 1,4-dioxane, and intermediate 1f (0.85 g, 2.88 mmol), cesium carbonate (1.17 g, 3.6 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthene (0.28 g, 0.48 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.11 g, 0.12 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 100°C for 17 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with ethyl acetate and water. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 2l (0.58 g, brown solid, yield 45%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0123] (4) Synthesis of the target product (R)-8-cyclopentyl-7-ethyl-2-((2-(2-hydroxyethoxy)-5-(piperazin-1-yl)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 2)

[0124] Step IV: 21 (0.58 g, 1.08 mmol) was dissolved in a mixture of methanol and water (volume ratio of 5:3) as a solvent, and then potassium carbonate (0.6 g, 4.32 mmol) was added to the reaction system, and the reaction was stirred at 40°C for 8 hours. After the reaction was completed, the volatile solvent was removed by concentration under reduced pressure, and compound 2 (209 mg, white solid, yield 39%) was obtained by column chromatography (petroleum ether: ethyl acetate = 6:1); 1 H NMR (600MHz, DMSO-d6) δ (ppm): 8.00 (d, J=2.5Hz, 1H), 7.81 (d, J=18.2Hz, 2H), 6.86 (d, J= 8.8Hz,1H),6.42(dd,J=8.7,2.7Hz,1H),5.05(s,1H),4.52(dd,J=16.3,8.3Hz,1H),4.17 (dd,J=8.1,3.7Hz,1H),3.97(t,J=4.6Hz,2H),3.70(s,2H),3.24(s,3H),2.96-2.88(m,4 H),2.88-2.78(m,4H),2.03-1.46(m,11H),0.78(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 496.3031.

[0125] Example 3

[0126] Synthesis of (R)-8-cyclopentyl-7-ethyl-2-((5-(4-ethylpiperazin-1-yl)-2-(2-hydroxyethoxy)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 3), the reaction route is as follows:

[0127]

[0128] (1) Synthesis of Intermediate 2-(4-(4-ethylpiperazin-1-yl)-2-nitrophenoxy)ethyl acetate (Intermediate 3j)

[0129] Step I: 1i (1.7 g, 5.59 mmol) was dissolved in 10 mL of anhydrous 1,4-dioxane, and ethylpiperazine (0.85 mL, 6.71 mmol), cesium carbonate (2.73 g, 8.385 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.65 g, 1.12 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was pumped out several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.51 g, 0.559 mmol) was quickly added, and the nitrogen was repeatedly pumped out with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 90°C for 18 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with water and ethyl acetate (100 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 3j (1.53 g, brown-yellow oil, yield 81%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0130] (2) Synthesis of Intermediate 2-(2-amino-4-(4-ethylpiperazin-1-yl)phenoxy)ethyl acetate (Intermediate 3k)

[0131] Step II: 3j (1.53 g, 4.54 mmol) was dissolved in a mixture of ethanol and water (volume ratio of 2:1) as a solvent, ammonium chloride (0.73 g, 13.62 mmol) was added, and reduced iron powder (1.27 g, 22.70 mmol) was slowly added. The mixture was stirred under reflux at 60°C for 2 hours. After the reaction was completed, diatomaceous earth was used for suction filtration, and the filtrate was collected. The filtrate was extracted with ethyl acetate and water (100 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, the intermediate 3k (0.71 g, brown solid, yield 51%) was obtained by column chromatography (ethyl acetate: methanol = 8:1).

[0132] (3) Synthesis of Intermediate (R)-2-(2-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(4-ethylpiperazin-1-yl)phenoxy)ethyl acetate (Intermediate 31)

[0133] Step III: 3k (0.71 g, 2.31 mmol) was dissolved in anhydrous 1,4-dioxane, and intermediate 1f (0.82 g, 2.77 mmol), cesium carbonate (1.51 g, 4.62 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthene (0.27 g, 0.46 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.21 g, 0.23 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 100°C for 15 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with ethyl acetate and water. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 3l (0.79 g, brown solid, yield 62%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0134] (4) Synthesis of the target product (R)-8-cyclopentyl-7-ethyl-2-((5-(4-ethylpiperazin-1-yl)-2-(2-hydroxyethoxy)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 3)

[0135] Step IV: 3l (0.79 g, 1.43 mmol) was dissolved in a mixture of methanol and water (volume ratio of 5:3) as a solvent, and then potassium carbonate (0.99 g, 7.15 mmol) was added to the reaction system, and the reaction was stirred at room temperature for 4 hours. After the reaction was completed, the volatile solvent was removed by concentration under reduced pressure, and compound 3 (496 mg, white solid, yield 66%) was obtained by column chromatography (petroleum ether: ethyl acetate = 6:1); 1H NMR (600MHz, CDCl3) δ (ppm): 8.12 (d, J = 2.8Hz, 1H), 7.74 (s, 1H), 7.61 (d, J = 15.1Hz, 1H), 6.81 (d, J = 8.7Hz, 1H), 6.50 (d d,J=8.7,2.8Hz,1H),4.69(dd,J=16.2,8.3Hz,1H),4.16(dd,J=8.3,3.8Hz,1H),4.12-4.09(m,2H),3.99-3.96(m,2H),3 .28(s,3H),3.17(dd,J=13.8,9.0Hz,4H),2.69-2.61(m,4H),2.52(q,J=7.2Hz,2H),2.21(s,1H),2.12-2.07(m,1H),2. 06-1.99(m,1H),1.84-1.73(m,3H),1.72-1.61(m,5H),1.15(t,J=7.2Hz,3H),0.90-0.84(m,3H); HRMS(ESI):m / z,(M+H) + , measured value 524.3348.

[0136] Example 4

[0137] Synthesis of (R)-4-(3-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(2-hydroxyethoxy)phenyl)piperazine-1-carboxylic acid tert-butyl ester (Compound 4), the reaction route is as follows:

[0138]

[0139] (1) Synthesis of Intermediate 4-(4-(2-acetoxyethoxy)-3-nitrophenyl)piperazine-1-carboxylic acid tert-butyl ester (Intermediate 4j)

[0140] Step I: 1i (1.7 g, 5.59 mmol) was dissolved in 10 mL of anhydrous 1,4-dioxane, and tert-butyl 1-carboxylate-piperazine (1.23 mL, 6.71 mmol), cesium carbonate (2.73 g, 8.385 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (0.65 g, 1.12 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.51 g, 0.559 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 110°C for 18 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with water and ethyl acetate (100 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 4j (1.81 g, brown-yellow oil, yield 79%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0141] (2) Synthesis of Intermediate 4-(4-(2-acetoxyethoxy)-3-aminophenyl)piperazine-1-carboxylic acid tert-butyl ester (Intermediate 4k)

[0142] Step II: 4j (1.81 g, 4.42 mmol) was dissolved in a mixture of ethanol and water (volume ratio of 2:1) as a solvent, ammonium chloride (0.71 g, 13.26 mmol) was added, and reduced iron powder (1.24 g, 22.10 mmol) was slowly added. The mixture was refluxed and stirred at 60°C for 2 hours. After the reaction was completed, diatomaceous earth was used for suction filtration, and the filtrate was collected. The filtrate was extracted with ethyl acetate and water (100 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, the intermediate 4k (0.62 g, white solid, yield 37%) was obtained by column chromatography (ethyl acetate: methanol = 8:1).

[0143] (3) Synthesis of Intermediate (R)-4-(4-(2-acetoxyethoxy)-3-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)phenyl)piperazine-1-carboxylic acid tert-butyl ester (Intermediate 41)

[0144] Step III: 4k (0.62 g, 1.63 mmol) was dissolved in anhydrous 1,4-dioxane, and intermediate 1f (0.58 g, 1.96 mmol), cesium carbonate (1.06 g, 3.26 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthene (0.19 g, 0.33 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.15 g, 0.16 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 110°C for 16 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with ethyl acetate and water. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 4l (0.63 g, white solid, yield 60%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0145] (4) Synthesis of the target product (R)-4-(3-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(2-hydroxyethoxy)phenyl)piperazine-1-carboxylic acid tert-butyl ester (Compound 4)

[0146] Step IV: 4l (0.63 g, 0.99 mmol) was dissolved in a mixture of methanol and water (volume ratio of 5:3) as a solvent, and then potassium carbonate (0.27 g, 1.98 mmol) was added to the reaction system, and the reaction was stirred at room temperature for 2 hours. After the reaction was completed, the volatile solvent was removed by concentration under reduced pressure, and compound 4 (347 mg, white solid, yield 59%) was obtained by column chromatography (petroleum ether: ethyl acetate = 8:1); 1H NMR (600MHz, DMSO-d6) δ (ppm): 8.00 (d, J = 2.5Hz, 1H), 7.80 (d, J = 7.0Hz, 2H), 6.86 (d, J = 8.8Hz, 1H), 6.47 (dd, J =8.8,2.7Hz,1H),5.03(s,1H),4.52(p,J=8.4Hz,1H),4.14(dd,J=8.1,3.7Hz,1H),3.95(t,J=4.6Hz,2H),3.69( dd,J=18.9,14.4Hz,2H),3.43(s,4H),3.21(s,3H),3.01-2.85(m,4H),1.93(dd,J=33.9,6.0Hz,2H),1.80(s,1 H),1.76-1.62(m,5H),1.61-1.47(m,3H),1.40(d,J=15.1Hz,9H),0.75(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) + , the measured value is 596.3557.

[0147] Example 5

[0148] Synthesis of (R)-tert-butyl (1-(3-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(2-hydroxyethoxy)phenyl)piperidin-4-yl)carbamate (Compound 5), the reaction route is as follows:

[0149]

[0150] (1) Synthesis of Intermediate 2-(4-(4-((tert-butyloxycarbonyl)amino)piperidin-1-yl)-2-nitrophenoxy)ethyl acetate (Intermediate 5j)

[0151] Step I: 1i (1.7 g, 5.59 mmol) was dissolved in 10 mL of anhydrous 1,4-dioxane, and 4-tert-butyloxycarbonyl-aminopiperidine (1.34 mL, 6.71 mmol), cesium carbonate (2.73 g, 8.385 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.65 g, 1.12 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was pumped out several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.51 g, 0.559 mmol) was quickly added, and the nitrogen was repeatedly pumped out with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 100°C for 15 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with water and ethyl acetate (100 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 5j (1.73, brown oil, yield 73%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0152] (2) Synthesis of Intermediate 2-(2-amino-4-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)phenoxy)ethyl acetate (Intermediate 5k)

[0153] Step II: 5j (1.81 g, 4.09 mmol) was dissolved in a mixture of ethanol and water (volume ratio of 2:1) as a solvent, ammonium chloride (0.66 g, 12.27 mmol) was added, and reduced iron powder (1.15 g, 20.45 mmol) was slowly added. The mixture was stirred under reflux at 60°C for 2 hours. After the reaction was completed, diatomaceous earth was used for suction filtration, and the filtrate was collected. The filtrate was extracted with ethyl acetate and water (100 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, the intermediate 5k (0.94 g, brown solid, yield 56%) was obtained by column chromatography (ethyl acetate: methanol = 8:1).

[0154] (3) Synthesis of Intermediate (R)-2-(4-(4-((tert-butyloxycarbonyl)amino)piperidin-1-yl)-2-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)phenoxy)ethyl acetate (Intermediate 51)

[0155] Step III: 5k (0.94 g, 2.39 mmol) was dissolved in anhydrous 1,4-dioxane, and intermediate 1f (0.85 g, 2.87 mmol), cesium carbonate (1.56 g, 4.78 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthene (0.69 g, 1.20 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.22 g, 0.24 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 120°C for 15 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with ethyl acetate and water. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 5l (1.06 g, brown solid, yield 68%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0156] (4) Synthesis of the target product (R)-tert-butyl (1-(3-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(2-hydroxyethoxy)phenyl)piperidin-4-yl)carbamate (Compound 5)

[0157] Step IV: Dissolve 51 (1.06 g, 1.63 mmol) in a mixture of methanol and water (volume ratio of 5:3) as a solvent, then add potassium carbonate (0.45 g, 3.26 mmol) to the reaction system, and stir at room temperature for 5 hours. After the reaction is completed, the volatile solvent is removed by concentration under reduced pressure, and compound 5 (615 mg, white solid, yield 62%) is obtained by column chromatography (petroleum ether: ethyl acetate = 8:1); 1H NMR (600MHz, DMSO-d6) δ (ppm): 8.01 (s, 1H), 7.83 (s, 1H), 7.79 (s, 1H), 6.85 (d, J = 8.6Hz, 2H), 6.45 (d, J = 8.4Hz ,1H),5.05(t,J=5.4Hz,1H),4.52(d,J=7.7Hz,1H),4.17(dd,J=7.6,3.3Hz,1H),3.97(s,2H),3.70(d,J=4.1Hz, 2H),3.43(d,J=11.4Hz,2H),3.24(s,3H),2.62(t,J=11.4Hz,2H),2.02-1.88(m,2H),1.75(dt,J=52.1,23.4Hz ,7H),1.64-1.45(m,5H),1.39(s,9H),1.19(dd,J=23.5,16.4Hz,1H),0.83-0.70(m,3H); HRMS(ESI):m / z,(M+H) + , measured value 610.3709.

[0158] Example 6

[0159] The synthesis of (R)-2-((5-(4-aminopiperidin-1-yl)-2-(2-hydroxyethoxy)phenyl)amino)-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 6) is as follows:

[0160]

[0161] Step I: Dissolve compound 5 (615 mg, 1.01 mmol) in 5 mL of dichloromethane, add 1 mL of trifluoroacetic acid dropwise to the reaction system under ice bath conditions, remove the ice bath after the reaction system is stable, and stir the reaction at room temperature for 12 hours. After the reaction is completed, concentrate under reduced pressure to remove the volatile liquid, and finally obtain compound 6 (457 mg, white solid, yield 89%) by column chromatography (ethyl acetate: methanol = 5:1); 1H NMR (600MHz, DMSO-d6) δ (ppm): 8.36 (s, 2H), 8.03 (s, 1H), 7.82 (d, J = 25.3Hz, 2H), 6.86 (d, J = 8.8Hz, 1H), 6.47 (d d,J=8.8,2.6Hz,1H),5.10(t,J=5.3Hz,1H),4.50(dd,J=16.1,8.2Hz,1H),4.17(dd,J=7.9,3.6Hz,1H),3.97(t,J =4.6Hz,2H),3.69(d,J=4.2Hz,2H),3.51(d,J=12.1Hz,2H),3.24(s,3H),3.07(t,J=11.4Hz,1H),2.65(t,J=11. 9Hz,2H),2.03-1.88(m,4H),1.80-1.65(m,7H),1.64-1.50(m,3H),0.77(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 510.3174.

[0162] Example 7

[0163] The synthesis of (R)-8-cyclopentyl-7-ethyl-2-((2-(3-hydroxypropoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 7) is as follows:

[0164]

[0165] (1) Synthesis of Intermediate 3-(4-bromo-2-nitrophenoxy)propan-1-ol (Intermediate 7h)

[0166] Step I: Weigh the raw material 4-bromo-2-nitrophenol (1.6 g, 7.34 mmol) into a thick-walled pressure bottle and dissolve it in a small amount of DMF solvent, add 3-bromo-1-propanol (1.64 mL, 18.13 mmol) to the reaction system, then add N,N-diisopropylethylamine (5.75 mL, 33.03 mmol) dropwise to the reaction system, and stir the reaction at 120°C for 3 h. After the reaction is completed, extract with water and ethyl acetate (100 mL×3), combine the organic phases, dry over anhydrous sodium sulfate, and concentrate under reduced pressure. Finally, column chromatography (petroleum ether: ethyl acetate = 6:1) is used to obtain intermediate 7h (1.68 g, orange-yellow solid, yield 83%).

[0167] (2) Synthesis of Intermediate 3-(4-bromo-2-nitrophenoxy)propyl acetate (Intermediate 7i)

[0168] Step II: 7h (1.68 g, 6.09 mmol) was dissolved in dichloromethane, and 4-dimethylaminopyridine (1.19 g, 9.74 mmol) and acetic anhydride (0.61 mL, 6.70 mmol) were added to the reaction system under ice bath conditions. After the system was stable, the ice bath was removed and the reaction was stirred at room temperature for 5 h. After the reaction was completed, the volatile solvent in the system was dried by spin drying, and the mixture was extracted with water and ethyl acetate (100 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and finally column chromatography (petroleum ether: ethyl acetate = 8:1) was used to obtain intermediate 7i (1.8 g, yellow-green oil, yield 93%).

[0169] (3) Synthesis of Intermediate 3-(4-(4-methylpiperazin-1-yl)-2-nitrophenoxy)propyl acetate (Intermediate 7j)

[0170] Step III: 7i (1.8 g, 5.66 mmol) was dissolved in 10 mL of anhydrous 1,4-dioxane, and 1-methylpiperazine (0.63 mL, 5.72 mmol), cesium carbonate (2.77 g, 8.49 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.65 g, 1.13 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was pumped out several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.52 g, 0.57 mmol) was quickly added, and the nitrogen was repeatedly pumped out with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 115°C for 18 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with water and ethyl acetate (100 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 7j (1.53 g, brown oil, yield 80%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0171] (4) Synthesis of Intermediate 3-(2-amino-4-(4-methylpiperazin-1-yl)phenoxy)propyl acetate (Intermediate 7k)

[0172] Step IV: 7j (1.53 g, 4.53 mmol) was dissolved in a mixture of ethanol and water (volume ratio of 2:1) as a solvent, ammonium chloride (0.73 g, 13.59 mmol) was added, and reduced iron powder (1.27 g, 24.9 mmol) was slowly added, and the mixture was refluxed and stirred at 60°C for 2 hours. After the reaction was completed, diatomaceous earth was used for suction filtration, and the filtrate was collected. The filtrate was extracted with ethyl acetate and water (100 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, the intermediate 7k (0.88 g, brown-yellow solid, yield 63%) was obtained by column chromatography (ethyl acetate: methanol = 8:1).

[0173] (5) Synthesis of Intermediate (R)-3-(2-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(4-methylpiperazin-1-yl)phenoxy)propyl acetate (Intermediate 71)

[0174] Step V: 7k (0.88 g, 2.86 mmol) was dissolved in anhydrous 1,4-dioxane, and intermediate 1f (1.01 g, 3.43 mmol), cesium carbonate (1.40 g, 4.29 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthene (0.83 g, 1.43 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.27 g, 0.29 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 110°C for 16 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with ethyl acetate and water. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 7l (1.02 g, brown solid, yield 65%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0175] (6) Synthesis of the target product (R)-8-cyclopentyl-7-ethyl-2-((2-(3-hydroxypropoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 7)

[0176] Step VI: 71 (1.02 g, 1.85 mmol) was dissolved in a mixture of methanol and water (volume ratio of 5:3) as a solvent, and then potassium carbonate (1.02 g, 7.40 mmol) was added to the reaction system and stirred in an oil bath at 80°C for 4 hours. After the reaction was completed, the volatile solvent was removed by concentration under reduced pressure, and compound 7 (456 mg, white solid, yield 47%) was obtained by column chromatography (petroleum ether: ethyl acetate = 6:1); 1 H NMR (600MHz, DMSO-d6) δ (ppm): 8.01 (s, 1H), 7.82 (s, 1H), 7.42 (s, 1H), 6.86 (d, J = 8.8Hz, 1H), 6.45 (dd, J =8.8,2.3Hz,1H),4.59(t,J=5.1Hz,1H),4.41-4.35(m,1H),4.19(dd,J=7.6,3.4Hz,1H),4.04(t,J=6.2Hz ,2H),3.59(dd,J=11.3,5.8Hz,2H),3.24(s,3H),3.00(s,4H),2.45(s,4H),2.21(s,3H),1.96-1.84(m,4H ),1.75(ddd,J=18.6,11.4,10.6Hz,5H),1.65-1.51(m,3H),0.77(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 524.3343.

[0177] Example 8

[0178] Synthesis of (R)-4-(3-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(3-hydroxypropoxy)phenyl)piperazine-1-carboxylic acid tert-butyl ester (Compound 8), the reaction scheme is as follows:

[0179]

[0180] (1) Synthesis of Intermediate 4-(4-(3-acetoxypropoxy)-3-nitrophenyl)piperazine-1-carboxylic acid tert-butyl ester (Intermediate 8j)

[0181] Step I: 7i (1.8 g, 5.66 mmol) was dissolved in 10 mL of anhydrous 1,4-dioxane, and tert-butyl 1-carboxylate-piperazine (1.27 mL, 6.79 mmol), cesium carbonate (2.77 g, 8.49 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (1.64 g, 2.83 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.52 g, 0.57 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 100°C for 18 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with water and ethyl acetate (100 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 8j (1.8 g, brown-yellow oil, yield 75%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0182] (2) Synthesis of Intermediate 4-(4-(3-acetoxypropoxy)-3-aminophenyl)piperazine-1-carboxylic acid tert-butyl ester (Intermediate 8k)

[0183] Step II: 8j (1.8 g, 4.25 mmol) was dissolved in a mixture of ethanol and water (volume ratio of 2:1) as a solvent, ammonium chloride (0.68 g, 12.75 mmol) was added, and reduced iron powder (1.19 g, 21.25 mmol) was slowly added, and the mixture was refluxed and stirred at 60°C for 2 hours. After the reaction was completed, diatomaceous earth was used for suction filtration, and the filtrate was collected. The filtrate was extracted with ethyl acetate and water (100 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, the intermediate 8k (0.99 g, yellow solid, yield 59%) was obtained by column chromatography (ethyl acetate: methanol = 8:1).

[0184] (3) Synthesis of Intermediate (R)-4-(4-(3-acetoxypropoxy)-3-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)phenyl)piperazine-1-carboxylic acid tert-butyl ester (Intermediate 81)

[0185] Step III: 8k (0.99 g, 2.52 mmol) was dissolved in anhydrous 1,4-dioxane, and intermediate 1f (0.89 g, 3.02 mmol), cesium carbonate (1.23 g, 3.78 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthene (0.30 g, 0.51 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.23 g, 0.25 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 120°C for 16 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with ethyl acetate and water. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 8l (1.15 g, off-white solid, yield 70%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0186] (4) Synthesis of the target product (R)-4-(3-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(3-hydroxypropoxy)phenyl)piperazine-1-carboxylic acid tert-butyl ester (Compound 8)

[0187] Step IV: 81 (1.15 g, 1.76 mmol) was dissolved in a mixture of methanol and water (volume ratio of 5:3) as a solvent, and then potassium carbonate (0.97 g, 7.04 mmol) was added to the reaction system, and the reaction was stirred at room temperature for 2 hours. After the reaction was completed, the volatile solvent was removed by concentration under reduced pressure, and compound 8 (777 mg, white solid, yield 55%) was obtained by column chromatography (petroleum ether: ethyl acetate = 8:1); 1H NMR (600MHz, CDCl3) δ (ppm): 7.89 (d, J = 28.4Hz, 1H), 7.63 (s, 1H), 7.46 (d, J = 19.8Hz, 1H), 6.61 (d, J = 8 .8Hz,1H),6.30(d,J=8.7Hz,1H),5.54(s,2H),4.51-4.33(m,1H),3.98(dd,J=7.6,3.1Hz,1H),3.69-3 .60(m,2H),3.37(s,4H),3.08(d,J=15.2Hz,3H),2.91-2.74(m,4H),1.91-1.80(m,5H),1.66-1.37(m, 8H), 1.29 (t, J=6.1Hz, 9H), 1.03 (tt, J=17.7, 8.8Hz, 1H), 0.67 (t, J=7.5Hz, 3H); HRMS (ESI): m / z, (M+H) + , the measured value is 610.3716.

[0188] Example 9

[0189] Synthesis of (R)-8-cyclopentyl-7-ethyl-2-((5-(4-ethylpiperazin-1-yl)-2-(3-hydroxypropoxy)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 9), the reaction route is as follows:

[0190]

[0191] (1) Synthesis of Intermediate 3-(4-(4-ethylpiperazin-1-yl)-2-nitrophenoxy)propyl acetate (Intermediate 9j)

[0192] Step I: 7i (1.8 g, 5.66 mmol) was dissolved in 10 mL of anhydrous 1,4-dioxane, and ethylpiperazine (0.86 mL, 6.79 mmol), cesium carbonate (2.77 g, 8.49 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (1.64 g, 2.83 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.52 g, 0.57 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 100°C for 18 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with water and ethyl acetate (100 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 9j (1.51 g, brown-yellow oil, yield 76%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0193] (2) Synthesis of Intermediate 3-(2-amino-4-(4-ethylpiperazin-1-yl)phenoxy)propyl acetate (Intermediate 9k)

[0194] Step II: 9j (1.51 g, 4.30 mmol) was dissolved in a mixture of ethanol and water (volume ratio of 2:1) as a solvent, ammonium chloride (0.69 g, 12.90 mmol) was added, and reduced iron powder (1.20 g, 21.50 mmol) was slowly added, and the mixture was refluxed and stirred at 60°C for 2 hours. After the reaction was completed, diatomaceous earth was used for suction filtration, and the filtrate was collected. The filtrate was extracted with ethyl acetate and water (100 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, the intermediate 9k (0.81 g, brown solid, yield 59%) was obtained by column chromatography (ethyl acetate: methanol = 8:1).

[0195] (3) Synthesis of Intermediate (R)-3-(2-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(4-ethylpiperazin-1-yl)phenoxy)propyl acetate (Intermediate 91)

[0196] Step III: 9k (0.81 g, 2.52 mmol) was dissolved in anhydrous 1,4-dioxane, and intermediate 1f (0.89 g, 3.02 mmol), cesium carbonate (1.23 g, 3.78 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthene (0.36 g, 1.26 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.23 g, 0.25 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 100°C for 15 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with ethyl acetate and water. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 9l (0.95 g, brown solid, yield 65%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0197] (4) Synthesis of the target product (R)-8-cyclopentyl-7-ethyl-2-((5-(4-ethylpiperazin-1-yl)-2-(3-hydroxypropoxy)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 9)

[0198] Step IV: 91 (0.95 g, 1.64 mmol) was dissolved in a mixture of methanol and water (volume ratio of 5:3) as a solvent, and then potassium carbonate (1.13 g, 8.20 mmol) was added to the reaction system, and the reaction was stirred at room temperature for 4 hours. After the reaction was completed, the volatile solvent was removed by concentration under reduced pressure, and compound 9 (334 mg, light yellow solid, yield 61%) was obtained by column chromatography (petroleum ether: ethyl acetate = 6:1); 1H NMR (600MHz, DMSO-d6) δ (ppm): 8.02 (d, J = 2.5Hz, 1H), 7.81 (s, 1H), 7.42 (s, 1H), 6.85 (d, J = 8.8Hz, 1H), 6.43 (d d,J=8.8,2.8Hz,1H),4.64(s,1H),4.18(dd,J=7.8,3.6Hz,1H),4.02(dt,J=13.8,6.7Hz,2H),3.58(t,J=6.2Hz, 2H),3.23(s,3H),3.05-2.93(m,4H),2.49-2.46(m,4H),2.34(q,J=7.2Hz,2H),2.00-1.84(m,4H),1.83-1.68(m ,5H),1.60(ddd,J=30.6,18.9,7.6Hz,4H),1.01(t,J=7.2Hz,3H),0.76(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 538.3501.

[0199] Example 10

[0200] The synthesis of (R)-8-cyclopentyl-7-ethyl-2-((2-(3-hydroxypropoxy)-5-(piperazin-1-yl)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 10) is as follows:

[0201]

[0202] Step I: Dissolve compound 8 (777 mg, 1.27 mmol) in 5 mL of dichloromethane, add 1 mL of trifluoroacetic acid dropwise to the reaction system under ice bath conditions, remove the ice bath after the reaction system is stable, and stir the reaction at room temperature for 12 hours. After the reaction is completed, concentrate under reduced pressure to remove the volatile liquid, and finally obtain compound 10 (591 mg, white solid, yield 91%) by column chromatography (ethyl acetate: methanol = 5:1); 1H NMR (600MHz, DMSO-d6) δ (ppm): 8.04 (s, 1H), 7.80 (d, J = 19.4Hz, 2H), 6.89 (d, J = 8.7Hz, 1H), 6.48 (d, J = 6.5Hz, 1H), 5.11 (s, 1H), 4.44 (d, J = 7.9Hz, 1H), 4.17(d,J=4.3Hz,1H),3.98(s,2H),3.70(s,3H),3.19(s,4H),3.09(s,4H), 2.10-1.47(m,11H),1.22(s,1H),0.86-0.69(m,3H); HRMS(ESI):m / z,(M+H) + , measured value 510.3190.

[0203] Embodiment 11

[0204] Synthesis of (R)-tert-butyl(1-(3-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(3-hydroxypropoxy)phenyl)pteridin-4-yl)carbamate (Compound 11), the reaction scheme is as follows:

[0205]

[0206] (1) Synthesis of Intermediate 3-(4-(4-((tert-butyloxycarbonyl)amino)piperidin-1-yl)-2-nitrophenoxy)propyl acetate (Intermediate 11j)

[0207] Step I: 7i (1.8 g, 5.66 mmol) was dissolved in 10 mL of anhydrous 1,4-dioxane, and 4-tert-butyloxycarbonyl-aminopiperidine (1.16 mL, 5.77 mmol), cesium carbonate (2.77 g, 8.49 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.65 g, 1.13 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.52 g, 0.57 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 125°C for 16 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with water and ethyl acetate (100 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 11j (2.03 g, brown oil, yield 82%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0208] (2) Synthesis of Intermediate 3-(2-amino-4-(4-((tert-butyloxycarbonyl)amino)piperidin-1-yl)phenoxy)propyl acetate (Intermediate 11k)

[0209] Step II: 11j (2.03 g, 4.64 mmol) was dissolved in a mixture of ethanol and water (volume ratio of 2:1) as a solvent, ammonium chloride (0.74 g, 13.92 mmol) was added, and reduced iron powder (1.30 g, 20.45 mmol) was slowly added. The mixture was refluxed and stirred at 60°C for 2 hours. After the reaction was completed, diatomaceous earth was used for suction filtration, and the filtrate was collected. The filtrate was extracted with ethyl acetate and water (100 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, the intermediate 11k (0.79 g, brown solid, yield 42%) was obtained by column chromatography (ethyl acetate: methanol = 8:1).

[0210] (3) Synthesis of Intermediate (R)-3-(4-(4-((tert-butyloxycarbonyl)amino)piperidin-1-yl)-2-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)phenoxy)propyl acetate (Intermediate 111)

[0211] Step III: 11k (0.79 g, 2.45 mmol) was dissolved in anhydrous 1,4-dioxane, and intermediate 1f (0.87 g, 2.94 mmol), cesium carbonate (1.20 g, 3.68 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthene (0.85 g, 1.47 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.23 g, 0.25 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 100°C for 18 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with ethyl acetate and water. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, the intermediate 11l (0.81 g, brown solid, yield 64%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0212] (4) Synthesis of the target product (R)-tert-butyl (1-(3-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(3-hydroxypropoxy)phenyl)pteridin-4-yl)carbamate (Compound 11)

[0213] Step IV: 111 (0.81 g, 1.24 mmol) was dissolved in a mixture of methanol and water (volume ratio of 5:3) as a solvent, and then potassium carbonate (0.51 g, 3.72 mmol) was added to the reaction system, and the reaction was stirred at room temperature for 5 hours. After the reaction was completed, the volatile solvent was removed by concentration under reduced pressure, and compound 11 (678 mg, white solid, yield 88%) was obtained by column chromatography (petroleum ether: ethyl acetate = 8:1); 1 H NMR (600MHz, DMSO-d6) δ (ppm): 8.02 (d, J = 2.0Hz, 1H), 7.84 (d, J = 19.6Hz, 1H), 7.44-7.37 (m, 1H), 6.85 (d, J=8.8Hz,2H),6.45(dd,J=8.8,2.6Hz,1H),4.57(t,J=5.0Hz,1H),4.39(s,1H),4.19(dd,J=7.8,3.6Hz,1H ),4.03(dt,J=13.0,6.7Hz,2H),3.65-3.54(m,2H),3.43(d,J=12.2Hz,2H),3.24(s,3H),2.63(t,J=11.6H z,2H),1.99-1.71(m,11H),1.65-1.46(m,5H),1.39(s,9H),0.77(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) + , the measured value is 624.3868.

[0214] Example 12

[0215] The synthesis of (R)-2-((5-(4-aminopiperidin-1-yl)-2-(3-hydroxypropoxy)phenyl)amino)-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 12) is as follows:

[0216]

[0217] Step I: Dissolve compound 11 (678 mg, 1.09 mmol) in 5 mL of dichloromethane, add 1 mL of trifluoroacetic acid dropwise to the reaction system under ice bath conditions, remove the ice bath after the reaction system is stable, and stir the reaction at room temperature for 12 hours. After the reaction is completed, concentrate under reduced pressure to remove the volatile liquid, and finally obtain compound 12 (512 mg, yellow solid, yield 90%) by column chromatography (ethyl acetate: methanol = 5:1); 1H NMR (600MHz, DMSO-d6) δ (ppm): 8.02 (d, J = 2.3Hz, 1H), 7.81 (s, 1H), 7.43 (d, J = 21.9Hz, 1H), 6.84 (d,J=8.8Hz,1H),6.44(dd,J=8.8,2.7Hz,1H),4.43(dd,J=32.6,25.1Hz,1H),4.18(dd,J=7.7,3. 6Hz,1H),4.08-3.99(m,2H),3.59(t,J=6.2Hz,2H),3.41(d,J=11.5Hz,2H),3.23(s,4H),2.67-2 .55(m,3H),2.02-1.47(m,15H),1.43-1.30(m,2H),0.76(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 524.3341.

[0218] Example 13

[0219] The synthesis of (R)-7-ethyl-2-((2-(2-hydroxyethoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 13) is as follows:

[0220]

[0221] (1) Synthesis of intermediate (R)-2-aminobutyric acid methyl ester (intermediate 1b)

[0222] Step I: Dissolve the commercially available raw material 1a (10 g, 96.97 mmol) in 120 mL of CH3OH, and slowly add SOCl2 (15 mL, 0.21 mmol) into the system at 0°C using a constant pressure separatory funnel. After the addition of SOCl2 is complete, remove the ice bath and the constant pressure separatory funnel, stir at room temperature for about 15 minutes, and then place the apparatus in a 60°C oil bath for reflux reaction for 2 h. Concentrate the reaction solution under reduced pressure, add 80 mL of petroleum ether for repeated washing, and filter to obtain a pure white solid, which is dried in a vacuum oven overnight to obtain intermediate 1b (10.3 g, pure white solid, yield 91%).

[0223] (2) Synthesis of intermediate (R)-2-(isopropylamino)butyric acid methyl ester (Intermediate 13c)

[0224] Step II: Add an appropriate amount of dichloromethane to a reaction vessel containing intermediate 1b (10.3 g, 55.60 mmol). At 0°C, observe the pH value of the reaction system first. If the reaction system is alkaline, add triethylamine dropwise to the reaction system until the system is weakly acidic (pH = 5-6). At this time, add acetone (5.33 mL, 58.37 mmol) in batches. After the reaction system is stable and does not release heat, remove the ice bath, stir and react at room temperature for 5 h, finally add sodium triacetoxyborohydride (16.76 g, 83.40 mmol) to the system, stir and react at room temperature for 18 h, and monitor the reaction at any time by fumigating the thin layer chromatography plate in an iodine cylinder to observe the changes in the raw material point and the product point. After the reaction of the raw materials was completed, the reaction was stopped and the reaction solution was neutralized with saturated sodium bicarbonate aqueous solution. A large number of bubbles were generated after ultrasonication. After the bubbles disappeared, the reaction solution was extracted with dichloromethane and water (100 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 13c (10.71 g, light brown oil, yield 80%).

[0225] (3) Synthesis of Intermediate (R)-2-((2-chloro-5-nitropyrimidin-4-yl)(isopropyl)amino)butyric Acid Methyl Ester (Intermediate 13d)

[0226] Step III: Under ice bath conditions, take the intermediate 13c (10.71 g, 70.35 mmol) and dissolve it in an appropriate amount of 1,2-dichloroethane, then add sodium bicarbonate (23.64 g, 281.40 mmol) to the reaction system, and finally add 2,4-dichloro-5-nitropyrimidine (10.92 g, 56.28 mmol), and reflux in an oil bath at 60°C for 18 h. After the raw materials are consumed, stop the reaction, first filter to remove the salt produced in the reaction, then extract with ethyl acetate and water (100 mL×3), combine the organic phases, dry over anhydrous sodium sulfate, concentrate under reduced pressure, and finally obtain the intermediate 13d (12.03 g, yellow oil, yield 54%) by column chromatography (petroleum ether: ethyl acetate = 15:1).

[0227] (4) Synthesis of Intermediate (R)-2-chloro-7-ethyl-8-isopropyl-7,8-dihydropteridin-6(5H)-one (Intermediate 13e)

[0228] Step IV: Dissolve the intermediate 13d (12.03 g, 37.98 mmol) in an appropriate amount of glacial acetic acid solvent, add reduced iron powder (10.63 g, 189.90 mmol) to the reaction system in batches, and reflux in an oil bath at 60°C for 2 h. Monitor the progress of the reaction by TLC, and stop the reaction when the raw materials are consumed. First, filter with diatomaceous earth, collect the filtrate, and extract the filtrate with ethyl acetate and water (100 mL×3), combine the organic phases, dry over anhydrous sodium sulfate, and concentrate under reduced pressure. Finally, column chromatography (petroleum ether: ethyl acetate = 2:1) is used to obtain the intermediate 13e (6.29 g, light yellow solid, yield 65%).

[0229] (5) Synthesis of Intermediate (R)-2-chloro-7-ethyl-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Intermediate 13f)

[0230] Step V: Dissolve the intermediate 13e (6.29 g, 24.69 mmol) in an appropriate amount of acetone, add anhydrous potassium carbonate (6.82 g, 49.38 mmol) and iodomethane (2.16 mL, 27.16 mmol), and reflux in an oil bath at 60°C for 2.5 h. Monitor the progress of the reaction by TLC, and stop the reaction when the raw materials are consumed. First, filter with diatomaceous earth, collect the filtrate, and extract the filtrate with ethyl acetate and water (100 mL×3), combine the organic phases, dry over anhydrous sodium sulfate, and concentrate under reduced pressure. Finally, column chromatography (petroleum ether: ethyl acetate = 2:1) is used to obtain the intermediate 13f (3.65 g, light yellow solid, yield 55%).

[0231] (6) Synthesis of Intermediate (R)-2-(2-((7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(4-methylpiperazin-1-yl)phenoxy)ethyl acetate (Intermediate 131)

[0232] Step VI: 1k (0.73 g, 2.48 mmol) was dissolved in anhydrous 1,4-dioxane, and intermediate 13f (0.80 g, 2.98 mmol), cesium carbonate (1.21 g, 3.72 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthene (0.29 g, 0.5 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.23 g, 0.25 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 110°C for 16 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with ethyl acetate and water. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 13l (0.82 g, off-white solid, yield 63%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0233] (7) Synthesis of the target product (R)-7-ethyl-2-((2-(2-hydroxyethoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 13)

[0234] Step VII: 131 (0.82 g, 1.56 mmol) was dissolved in a mixture of methanol and water (volume ratio of 5:3) as a solvent, and then potassium carbonate (0.65 g, 4.68 mmol) was added to the reaction system and stirred at room temperature for 5 hours. After the reaction was completed, the volatile solvent was removed by concentration under reduced pressure, and compound 13 (490 mg, light yellow solid, yield 65%) was obtained by column chromatography (petroleum ether: ethyl acetate = 6:1); 1 H NMR (600MHz, DMSO-d6) δ (ppm): 8.11 (d, J = 2.8Hz, 1H), 7.84 (d, J = 3.6Hz, 1H), 6.88 (d, J = 8.7H z,1H),6.44(dd,J=8.7,2.6Hz,1H),4.81-4.71(m,1H),4.26(dd,J=7.9,3.3Hz,1H),3.99(t,J =4.8Hz,1H),3.76-3.70(m,2H),3.26(s,3H),3.03(d,J=4.5Hz,3H),2.24(s,2H),1.65(s,11H ),1.35(d,J=6.7Hz,3H),1.30(d,J=6.8Hz,3H),0.79(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) +, the measured value is 484.3038.

[0235] Embodiment 14

[0236] The synthesis of (R)-7-ethyl-2-((2-(2-hydroxyethoxy)-5-(piperazin-1-yl)phenyl)amino)-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 14) is as follows:

[0237]

[0238] (1) Synthesis of Intermediate (R)-2-(2-((7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(piperazin-1-yl)phenoxy)ethyl acetate (Intermediate 141)

[0239] Step I: 2k (0.67 g, 2.40 mmol) was dissolved in anhydrous 1,4-dioxane, and intermediate 13f (0.77 g, 2.88 mmol), cesium carbonate (1.17 g, 3.6 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (0.28 g, 0.48 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.11 g, 0.12 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 100°C for 17 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with ethyl acetate and water. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 14l (0.80 g, white solid, yield 65%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0240] (2) Synthesis of the target product (R)-7-ethyl-2-((2-(2-hydroxyethoxy)-5-(piperazin-1-yl)phenyl)amino)-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 14)

[0241] Step II: 141 (0.80 g, 1.56 mmol) was dissolved in a mixture of methanol and water (volume ratio of 5:3) as a solvent, and then potassium carbonate (0.86 g, 6.24 mmol) was added to the reaction system, and the mixture was stirred at 50°C for 5 hours. After the reaction was completed, the volatile solvent was removed by concentration under reduced pressure, and compound 14 (360 mg, white solid, yield 49%) was obtained by column chromatography (petroleum ether: ethyl acetate = 6:1);1 H NMR (600MHz, DMSO-d6) δ (ppm): 8.09 (s, 1H), 7.86-7.79 (m, 2H), 6.85 (d, J = 8.7Hz, 1H), 6.40 (d, J = 6.6Hz, 1 H),5.14(s,1H),4.75(dt,J=13.6,6.7Hz,1H),4.26-4.20(m,1H),3.96(s,2H),3.71(d,J=4.3Hz,2H),3.23 (s,3H),2.92(d,J=4.6Hz,4H),2.82(s,3H),2.61(s,1H),1.77-1.72(m,1H),1.70(s,1H),1.67-1.59(m,1H ),1.33(d,J=6.7Hz,3H),1.28(t,J=7.3Hz,3H),1.22(s,1H),0.76(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) + , the measured value is 470.2878.

[0242] Embodiment 15

[0243] The synthesis of (R)-7-ethyl-2-((5-(4-ethylpiperazin-1-yl)-2-(2-hydroxyethoxy)phenyl)amino)-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 15) is as follows:

[0244]

[0245] (1) Synthesis of Intermediate (R)-2-(2-((7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(4-ethylpiperazin-1-yl)phenoxy)ethyl acetate (Intermediate 151)

[0246] Step I: 3k (0.71 g, 2.31 mmol) was dissolved in anhydrous 1,4-dioxane, and intermediate 13f (0.74 g, 2.77 mmol), cesium carbonate (1.51 g, 4.62 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.27 g, 0.46 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.21 g, 0.23 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 100°C for 15 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with ethyl acetate and water. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 15l (0.82 g, brown solid, yield 66%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0247] (2) Synthesis of the target product (R)-7-ethyl-2-((5-(4-ethylpiperazin-1-yl)-2-(2-hydroxyethoxy)phenyl)amino)-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 15)

[0248] Step II: 151 (0.82 g, 1.52 mmol) was dissolved in a mixture of methanol and water (volume ratio of 5:3) as a solvent, and then potassium carbonate (0.63 g, 4.56 mmol) was added to the reaction system, and the reaction was stirred at room temperature for 5 hours. After the reaction was completed, the volatile solvent was removed by concentration under reduced pressure, and compound 15 (416 mg, white solid, yield 55%) was obtained by column chromatography (petroleum ether: ethyl acetate = 6:1); 1H NMR (600MHz, DMSO-d6) δ (ppm): 8.10 (d, J = 2.9 Hz, 1H), 7.83 ( d, J = 15.1 Hz, 2H), 6.85 ( d, J = 8.7 Hz, 1H), 6.42 ( dd, J = 8.7, 2 .9Hz,1H),5.11(t,J=5.6Hz,1H),4.74(p,J=6.9Hz,1H),4.25(dd,J=8.0,3.5Hz,1H),3.96(hept,J=5.1Hz,2H),3.71(q ,J=5.0Hz,2H),3.24(s,4H),3.02(t,J=4.9Hz,4H),2.37(q,J=7.1Hz,2H),1.75(ddt,J=13.5,9.4,6.7Hz,1H),1.63(dp ,J=14.8,7.4Hz,1H),1.30(dd,J=33.0,6.8Hz,7H),1.03(t,J=7.2Hz,3H),0.77(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) + , the measured value is 498.3212.

[0249] Example 16

[0250] The synthesis of (R)-7-ethyl-2-((2-(3-hydroxypropoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 16) is as follows:

[0251]

[0252] (1) Synthesis of Intermediate (R)-3-(2-((7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(4-methylpiperazin-1-yl)phenoxy)propyl acetate (Intermediate 161)

[0253] Step I: 7k (0.88 g, 2.86 mmol) was dissolved in anhydrous 1,4-dioxane, and intermediate 13f (0.92 g, 3.43 mmol), cesium carbonate (1.40 g, 4.29 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (0.83 g, 1.43 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.27 g, 0.29 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 110°C for 16 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with ethyl acetate and water. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 16l (1.04 g, brown solid, yield 67%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0254] (2) Synthesis of the target product (R)-7-ethyl-2-((2-(3-hydroxypropoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 16)

[0255] Step II: 161 (1.04 g, 1.93 mmol) was dissolved in a mixture of methanol and water (volume ratio of 5:3) as a solvent, and then potassium carbonate (0.80 g, 5.79 mmol) was added to the reaction system, and the reaction was stirred at room temperature for 5 hours. After the reaction was completed, the volatile solvent was removed by concentration under reduced pressure, and compound 16 (595 mg, light yellow solid, yield 62%) was obtained by column chromatography (petroleum ether: ethyl acetate = 6:1); 1H NMR(600MHz,DMSO-d6)δ(ppm):8.10(dd,J=22.5,2.8Hz,1H),7.80(s,1H),7.47(d,J=13.6Hz,1H),6.91(dd,J=24.4,8.8Hz,1 H),6.47(dd,J=8.8,2.8Hz,1H),4.66(dq,J=13.9,6.9Hz,1H),4.25(dd,J=7.9,3.4Hz,1H),4.06(t,J=6.2Hz,2H),3.23(s,3H ),3.13(s,4H),3.07(q,J=7.3Hz,3H),2.84(s,4H),1.92-1.86(m,2H),1.76(dqd,J=15.0,7.5,3.5Hz,1H),1.64(dp,J=14.9, 7.4Hz,1H),1.34(d,J=6.8Hz,3H),1.29(d,J=6.8Hz,3H),1.18(t,J=7.3Hz,3H),0.76(t,J=7.5Hz,3H); HRMS(ESI):m / z,(M+H) + , the measured value is 498.3176.

[0256] Embodiment 17

[0257] The synthesis of (R)-7-ethyl-2-((2-(3-hydroxypropoxy)-5-(piperazin-1-yl)phenyl)amino)-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 17) is as follows:

[0258]

[0259] (1) Synthesis of Intermediate 3-(2-amino-4-(piperazin-1-yl)phenoxy)propyl acetate (Intermediate 171)

[0260] Step I: Compound 8k (0.99 g, 2.52 mmol) was dissolved in 5 mL of dichloromethane, and 1 mL of trifluoroacetic acid was added dropwise to the reaction system under ice bath conditions. After the reaction system was stable, the ice bath was removed and the reaction was stirred at room temperature for 12 hours. After the reaction was completed, the volatile liquid was removed by vacuum concentration, and finally the intermediate 17l (0.65 g, gray solid, yield 88%) was obtained by column chromatography (ethyl acetate: methanol = 5:1).

[0261] (2) Synthesis of Intermediate (R)-3-(2-((7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(piperazin-1-yl)phenoxy)propyl acetate (Intermediate 17m)

[0262] Step II: 17l (0.65 g, 2.22 mmol) was dissolved in anhydrous 1,4-dioxane, and intermediate 13f (0.72 g, 2.67 mmol), cesium carbonate (1.08 g, 3.33 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthene (0.64 g, 1.11 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.20 g, 0.22 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 110°C for 16 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with ethyl acetate and water. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 17m (0.78 g, white solid, yield 67%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0263] (3) Synthesis of the target product (R)-7-ethyl-2-((2-(3-hydroxypropoxy)-5-(piperazin-1-yl)phenyl)amino)-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 17)

[0264] Step III: Dissolve 17m (0.78 g, 1.48 mmol) in a mixture of methanol and water (volume ratio of 5:3) as solvent, then add potassium carbonate (1.02 g, 7.40 mmol) to the reaction system, and stir at room temperature for 4 hours. After the reaction is completed, concentrate under reduced pressure to remove the volatile solvent, and obtain compound 17 (632 mg, white solid, yield 88%) by column chromatography (petroleum ether: ethyl acetate = 6:1); 1H NMR (600MHz, DMSO-d6) δ (ppm): 8.08 (d, J = 2.7Hz, 1H), 7.80 (s, 1H), 7.44 (s, 1H), 6.87 (d, J = 8.8Hz, 1H), 6.43 (dd, J = 8.8, 2. 7Hz,1H),4.69(dt,J=13.6,6.7Hz,1H),4.25(dd,J=7.8,3.4Hz,1H),4.05(t,J=6.2Hz,2H),3.58(t,J=6.2Hz,2H),3.23(s,3 H),3.03(s,1H),2.99-2.95(m,3H),2.90-2.86(m,3H),2.61(s,1H),1.88(p,J=6.2Hz,2H),1.76(ddd,J=14.2,7.4,3.4Hz, 1H), 1.63 (dt, J=22.0, 7.5Hz, 1H), 1.31 (dd, J=30.6, 6.8Hz, 6H), 1.22 (s, 1H), 0.76 (t, J=7.4Hz, 3H); HRMS (ESI): m / z, (M+H) + , the measured value is 484.3036.

[0265] Embodiment 18

[0266] Synthesis of (R)-8-cyclopentyl-7-ethyl-2-((3-fluoro-2-(3-hydroxypropoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 18), the reaction scheme is as follows:

[0267]

[0268] Referring to the preparation of compound 7, 4-bromo-2-fluoro-6-nitrophenol (raw material 1.8 g) was used instead of 4-bromo-2-nitrophenol (raw material 1 g) according to the same feed ratio to obtain the title compound 18 (489 mg, white solid, yield 51%); 1HNMR(600MHz,DMSO-d6)δ(ppm):7.82(s,1H),7.76(d,J=6.2Hz,1H),7.64(s,1H),6.40(d,J=14.3Hz,1H),4.56( t,J=5.1Hz,1H),4.35(dt,J=8.3,5.3Hz,1H),4.20(dd,J=7.7,3.6Hz,1H),4.01(t,J=6.2Hz,2H),3.58(dd,J=13 .4,6.8Hz,2H),3.24(s,3H),3.09-3.03(m,4H),2.45-2.41(m,4H),2.21(s,3H),1.98-1.87(m,2H),1.86-1.70( m,7H),1.61(dt,J=21.9,7.5Hz,1H),1.54(dd,J=17.5,7.4Hz,2H),0.76(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 542.3250.

[0269] Embodiment 19

[0270] The synthesis of (R)-7-ethyl-2-((3-fluoro-2-(3-hydroxypropoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 19) is as follows:

[0271]

[0272] Referring to the preparation of compound 16, 4-bromo-2-fluoro-6-nitrophenol (raw material 1.8 g) was used instead of 4-bromo-2-nitrophenol (raw material 1 g) according to the same feed ratio to obtain the title compound 19 (771 mg, white solid, yield 65%); 1HNMR(600MHz,DMSO-d6)δ(ppm):7.84(d,J=11.6Hz,1H),7.82(s,1H),7.67(s,1H),6.37(d,J=1 3.8Hz,1H),4.69-4.62(m,1H),4.61(s,1H),4.26(d,J=4.3Hz,1H),4.02(s,2H),3.60(s,2H),3 .23(s,3H),3.07(s,4H),2.43(s,4H),2.21(s,3H),1.89-1.81(m,2H),1.76(s,1H),1.64(dd,J =13.9,6.9Hz,1H),1.30(dd,J=25.2,6.0Hz,6H),0.76(t,J=6.8Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 516.3026.

[0273] Embodiment 20

[0274] The synthesis of (R)-8-cyclopentyl-7-ethyl-2-((3-fluoro-2-(2-hydroxyethoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 20) is as follows:

[0275]

[0276] Referring to the preparation of compound 1, 4-bromo-2-fluoro-6-nitrophenol (raw material 18 g) was used instead of 4-bromo-2-nitrophenol (raw material 1 g) according to the same feed ratio to obtain the title compound 20 (385 mg, white solid, yield 48%); 1 H NMR (600MHz, DMSO-d6) δ (ppm): 8.28 (s, 1H), 7.85 (d, J = 23.8Hz, 2H), 6.37 (d ,J=13.4Hz,1H),5.19(s,1H),4.42(s,1H),4.18(s,1H),3.96(s,2H),3.63( s,2H),3.24(s,3H),3.07(s,4H),2.43(s,4H),2.21(s,3H),1.94(d,J=40.4 Hz,2H),1.75(s,5H),1.64-1.50(m,3H),0.77(s,3H); HRMS(ESI):m / z,(M+H) + , the measured value is 528.3093.

[0277] Embodiment 21

[0278] The synthesis of (R)-7-ethyl-2-((3-fluoro-2-(2-hydroxyethoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 21) is as follows:

[0279]

[0280] Referring to the preparation of compound 13, 4-bromo-2-fluoro-6-nitrophenol (raw material 1.8 g) was used instead of 4-bromo-2-nitrophenol (raw material 1 g) according to the same feed ratio to obtain the title compound 21 (475 mg, white solid, yield 56%); 1 HNMR(600MHz,DMSO-d6)δ(ppm):8.38(s,1H),7.95(s,1H),7.82(s,1H),6.34(d,J=12.7H z,1H),5.29(s,1H),4.69-4.61(m,1H),4.27-4.23(m,1H),4.01-3.92(m,2H),3.65(s,2H) ,3.24(s,3H),3.07(s,4H),2.43(s,4H),2.20(s,3H),1.79-1.72(m,1H),1.63(dt,J=14. 3,7.3Hz,1H),1.30(dd,J=23.8,6.6Hz,6H),0.76(t,J=7.3Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 502.2938.

[0281] Embodiment 22

[0282] The synthesis of (R)-2-((3-chloro-2-(2-hydroxyethoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 22) is as follows:

[0283]

[0284] Referring to the preparation of compound 1, 4-bromo-2-chloro-6-nitrophenol (raw material 2.2 g) was used instead of 4-bromo-2-nitrophenol (raw material 1 g) according to the same feed ratio to obtain the title compound 22 (550 mg, white solid, yield 63%); 1HNMR(600MHz,DMSO-d6)δ(ppm):8.52(s,1H),8.06(d,J=3.0Hz,1H),7.83(s,1H),6.51(d,J=2.9Hz,1H),5.35(s,1H), 4.42(p,J=8.3Hz,1H),4.19(dd,J=8.0,3.7Hz,1H),3.98-3.89(m,2H),3.66(t,J=4.6Hz,2H),3.24(s,3H),3.07(t,J=5 .0Hz,4H),2.43(t,J=5.0Hz,4H),2.21(s,3H),1.98(tt,J=8.7,6.7,5.5Hz,1H),1.94-1.86(m,1H),1.73(tdd,J=18.2 ,9.3,5.6Hz,5H),1.64-1.57(m,1H),1.53(tdd,J=12.0,5.5,2.7Hz,2H),0.77(t,J=7.5Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 544.2792.

[0285] Embodiment 23

[0286] The synthesis of (R)-2-((3-chloro-2-(2-hydroxyethoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-7-ethyl-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 23) is as follows:

[0287]

[0288] With reference to the preparation of compound 13, 4-bromo-2-chloro-6-nitrophenol (raw material 2.2 g) was used instead of 4-bromo-2-nitrophenol (raw material 1 g) according to the same feed ratio to obtain the title compound 23 (498 mg, light yellow solid, yield 53%); 1H NMR (600MHz, DMSO-d6) δ (ppm): 8.59 (s, 1H), 8.15 (t, J = 2.4Hz, 1H), 7.82 (s, 1H), 6.48 (d, J = 2.8Hz, 1H), 4 .63(p,J=6.8Hz,1H),4.25(dd,J=7.8,3.4Hz,1H),3.98-3.88(m,2H),3.67(td,J=4.2,2.3Hz,2H),3.08(t ,J=5.0Hz,4H),2.44(t,J=5.0Hz,4H),2.21(s,3H),1.76(dqd,J=14.9,7.5,3.3Hz,1H),1.68-1.59(m,1H) ,1.39(s,1H),1.32(d,J=6.8Hz,3H),1.28(d,J=6.9Hz,3H),0.76(t,J=7.5Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 518.2630.

[0289] Embodiment 24

[0290] The synthesis of (R)-8-cyclopentyl-7-ethyl-2-((3-fluoro-2-((S)-2-hydroxypropoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 24) is as follows:

[0291]

[0292] Referring to the preparation of compound 1, 4-bromo-2-fluoro-6-nitrophenol (raw material 1.8 g) was used instead of 4-bromo-2-nitrophenol (raw material 1 g) according to the same feed ratio, and (S)-1-bromo-2-propanol was used instead of 2-bromoethanol to obtain the title compound 24 (521 mg, white solid, yield 52%); 1H NMR (600MHz, DMSO-d6) δ (ppm): 8.47-8.29 (m, 1H), 7.91 (s, 2H), 6.39 (dt, J = 14.8, 4.0Hz, 1H), 5.25 (s, 1H), 4.44 (s, 1H) ,4.19(dt,J=7.1,3.2Hz,1H),3.91(s,1H),3.68(ddd,J=19.3,10.2,7.3Hz,1H),3.49(h,J=5.9,5.3Hz,1H),3.24(s,3H ),3.07(q,J=4.5Hz,4H),2.49(s,4H),2.22(d,J=3.1Hz,3H),1.99-1.88(m,2H),1.81-1.69(m,5H),1.53(hept,J=6.3, 5.0Hz, 2H), 1.22 (td, J=7.0, 6.3, 3.0Hz, 2H), 1.11 (dd, J=6.4, 1.6Hz, 2H), 0.77 (t, J=7.4Hz, 3H); HRMS (ESI): m / z, (M+H) + , measured value 542.3240.

[0293] Embodiment 25

[0294] The synthesis of (R)-7-ethyl-2-((3-fluoro-2-((S)-2-hydroxypropoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 25) is as follows:

[0295]

[0296] Referring to the preparation of compound 13, 4-bromo-2-fluoro-6-nitrophenol (raw material 1.8 g) was used instead of 4-bromo-2-nitrophenol (raw material 1 g) according to the same feed ratio, and (S)-1-bromo-2-propanol was used instead of 2-bromoethanol to obtain the title compound 25 (467 mg, white solid, yield 47%); 1H NMR (600MHz, DMSO-d6) δ (ppm): 8.59-8.37 (m, 1H), 8.00-7.87 (m, 1H), 7.81 (d, J = 2.4Hz, 1H), 6.35 (dq, J = 13.9, 3.0Hz, 1H ),5.43-5.20(m,1H),4.65(h,J=6.8Hz,1H),4.25(dt,J=7.0,3.2Hz,1H),3.98-3.84(m,2H),3.54-3.50(m,1H),3.23(s, 3H),3.07(dt,J=6.5,3.7Hz,4H),2.44(t,J=4.9Hz,4H),2.22(s,3H),1.76(dqd,J=15.1,7.6,6.9,3.2Hz,1H),1.63(tqd ,J=10.9,7.0,2.5Hz,1H),1.35-1.26(m,6H),1.21(dd,J=10.1,6.2Hz,3H),0.76(t,J=7.5Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 516.3091.

[0297] Embodiment 26

[0298] The synthesis of (R)-8-cyclopentyl-2-((5-((2-(dimethylamino)ethyl)(methyl)amino)-3-fluoro-2-(3-hydroxypropoxy)phenyl)amino)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 26) is as follows:

[0299]

[0300] Referring to the preparation of compound 18, compound N1,N1,N2-trimethylethane-1,2-diamine was used to replace methylpiperazine according to the same feed ratio to obtain the title compound 26 (612 mg, light yellow solid, yield 73%); 1H NMR (600MHz, DMSO-d6) δ (ppm): 7.76 (d, J=1.0Hz, 1H), 7.58 (d, J=6.9Hz, 2H), 6.11 (ddd, J=14.7, 3.0, 1.6Hz, 1H), 4.57 (s, 1H), 4.33(pd,J=8.4,3.4Hz,1H),4.20(dd,J=7.7,3.6Hz,1H),3.97(td,J=6.4,1.4Hz,2H),3.63-3.55(m,2H),3.37(s,1H),3.23(s ,3H),2.87(s,3H),2.35(t,J=7.2Hz,2H),2.17(s,6H),1.95(dq,J=10.1,7.5,6.8Hz,1H),1.88-1.80(m,4H),1.74(tdd,J=11. 1,7.1,3.5Hz,3H),1.67-1.59(m,1H),1.58-1.47(m,2H),1.23(t,J=3.0Hz,1H),0.76(t,J=7.5Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 544.3404.

[0301] Embodiment 27

[0302] Synthesis of (R)-2-((3-chloro-2-(3-hydroxypropoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-7-ethyl-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 27), the reaction scheme is as follows:

[0303]

[0304] Referring to the preparation of compound 16, 4-bromo-2-chloro-6-nitrophenol (raw material 2.2 g) was used instead of 4-bromo-2-nitrophenol (raw material 1 g) according to the same feed ratio to obtain the title compound 27 (432 mg, white solid, yield 45%); 1HNMR(600MHz,DMSO-d6)δ(ppm):7.99(d,J=2.8Hz,1H),7.83(s,1H),7.72(s,1H),6.53(d,J=2.9Hz,1H),4.63(h ,J=6.8Hz,2H),4.26(dd,J=7.9,3.4Hz,1H),3.95(td,J=6.3,1.9Hz,2H),3.63(t,J=6.3Hz,2H),3.24(s,3H),3.0 8(t,J=5.0Hz,4H),2.44(t,J=5.0Hz,4H),2.22(s,3H),1.88(p,J=6.3Hz,2H),1.77(dqd,J=15.0,7.5,3.3Hz,1H ),1.68-1.57(m,1H),1.33(d,J=6.8Hz,3H),1.29(d,J=6.9Hz,3H),0.76(t,J=7.5Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 532.2779.

[0305] Embodiment 28

[0306] Synthesis of (R)-2-((3-chloro-2-(3-hydroxypropoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 28), the reaction scheme is as follows:

[0307]

[0308] Referring to the preparation of compound 7, 4-bromo-2-chloro-6-nitrophenol (raw material 2.2 g) was used instead of 4-bromo-2-nitrophenol (raw material 1 g) according to the same feed ratio to obtain the title compound 28 (525 mg, white solid, yield 50%); 1HNMR(600MHz,DMSO-d6)δ(ppm):7.87(d,J=2.9Hz,1H),7.82(d,J=1.3Hz,1H),7.69(s,1H),6.56(d,J=2.6H z,1H),4.57(t,J=5.1Hz,1H),4.32(p,J=8.4Hz,1H),4.20(dd,J=8.1,3.5Hz,1H),3.93(t,J=6.4Hz,2H),3.6 0(q,J=6.0Hz,2H),3.07(t,J=5.0Hz,4H),2.43(t,J=4.9Hz,4H),2.21(s,3H),1.93(q,J=8.6Hz,1H),1.90- 1.68(m,8H),1.62(dp,J=14.9,7.4Hz,1H),1.58-1.46(m,2H),0.76(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) + , the measured value is 558.2942.

[0309] Embodiment 29

[0310] Synthesis of (R)-8-cyclopentyl-7-ethyl-2-((5-(4-ethylpiperazin-1-yl)-3-fluoro-2-(2-hydroxyethoxy)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 29), the reaction scheme is as follows:

[0311]

[0312] Referring to the preparation of compound 3, 4-bromo-2-fluoro-6-nitrophenol (raw material 1.8 g) was used instead of 4-bromo-2-nitrophenol (raw material 1 g) according to the same feed ratio to obtain the title compound 29 (439 mg, light yellow solid, yield 56%); 1HNMR(600MHz,DMSO-d6)δ(ppm):8.30(s,1H),7.88-7.79(m,2H),6.37(dq,J=14.0,2.6Hz,1H),5.21(d,J=5.3Hz,1H ),4.41(q,J=8.2Hz,1H),4.16(dd,J=8.1,4.1Hz,1H),3.93(tq,J=11.7,6.7,5.6Hz,2H),3.60(d,J=5.0Hz,2H),3.22 (d,J=1.9Hz,3H),3.04(t,J=5.1Hz,4H),2.37-2.29(m,2H),2.01-1.84(m,3H),1.78-1.66(m,5H),1.56(ddt,J=32. 5,13.1,7.3Hz,3H),1.30-1.17(m,2H),1.00(ddt,J=7.2,4.3,2.3Hz,3H),0.78-0.72(m,3H); HRMS(ESI):m / z,(M+H) + , measured value 542.3254.

[0313] Embodiment 30

[0314] The synthesis of (R)-8-cyclopentyl-7-ethyl-2-((2-methoxy-5-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 30) is as follows:

[0315]

[0316] (1) Synthesis of intermediate 4-bromo-1-methoxy-2-nitrobenzene (intermediate 30h)

[0317] Step I: Dissolve 1g (1.6g, 7.34mmol) in an appropriate amount of acetone, add anhydrous potassium carbonate (3.04g, 22.02mmol) and iodomethane (0.52mL, 8.07mmol), and reflux in an oil bath at 60°C for 4.5h. Monitor the progress of the reaction by TLC, and stop the reaction when the raw materials are consumed. Extract the reaction solution with ethyl acetate and water (100mL×3), combine the organic phases, dry over anhydrous sodium sulfate, and concentrate under reduced pressure. Finally, column chromatography (petroleum ether: ethyl acetate = 2:1) is used to obtain intermediate 30h (1.46g, yellow solid, yield 86%).

[0318] (2) Synthesis of Intermediate 1-(4-methoxy-3-nitrophenyl)-4-methylpiperazine (Intermediate 30i)

[0319] Step II: 30h (1.46 g, 6.29 mmol) was dissolved in 10 mL of anhydrous 1,4-dioxane, and 1-methylpiperazine (0.71 mL, 6.35 mmol), cesium carbonate (3.08 g, 9.44 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthene (1.82 g, 3.15 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was pumped out several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.58 g, 0.63 mmol) was quickly added, and the nitrogen was repeatedly pumped out with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 110°C for 18 hours. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with water and ethyl acetate (100 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, the intermediate 30i (1.14 g, brown oil, yield 72%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0320] (3) Synthesis of Intermediate 2-methoxy-5-(4-methylpiperazin-1-yl)aniline (Intermediate 30j)

[0321] Step III: 30i (1.14 g, 4.54 mmol) was dissolved in a mixture of ethanol and water (volume ratio of 2:1) as a solvent, ammonium chloride (0.73 g, 13.62 mmol) was added, and reduced iron powder (1.27 g, 20.35 mmol) was slowly added, and the mixture was refluxed and stirred at 60°C for 2 hours. After the reaction was completed, diatomaceous earth was used for suction filtration, and the filtrate was collected. The filtrate was extracted with ethyl acetate and water (100 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, the intermediate 30j (0.49 g, yellow solid, yield 49%) was obtained by column chromatography (ethyl acetate: methanol = 8:1).

[0322] (4) Synthesis of the target product (R)-8-cyclopentyl-7-ethyl-2-((2-methoxy-5-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Intermediate 30k)

[0323] Step IV: 30j (0.49 g, 2.21 mmol) was dissolved in anhydrous 1,4-dioxane, and intermediate 1f (0.78 g, 2.65 mmol), cesium carbonate (1.08 g, 3.32 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthene (0.25 g, 0.44 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle, and the nitrogen was replaced several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.20 g, 0.22 mmol) was quickly added, and the nitrogen was repeatedly replaced with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 140°C for 15 hours. After the reaction solution was cooled to room temperature, the reaction solution was filtered and washed with ethyl acetate, the filtrate was collected, extracted with ethyl acetate and water, the organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and finally column chromatography (ethyl acetate: methanol = 10: 1) was performed to obtain compound 30 (584 mg, white solid, yield 55%); 1 H NMR (600MHz, DMSO-d6) δ (ppm): 7.98 (d, J = 2.7Hz, 1H), 7.81 (s, 1H), 7.40 (s, 1H), 6.86 (t,J=16.2Hz,1H),6.46(dd,J=8.8,2.8Hz,1H),4.53-4.41(m,1H),4.16(dd,J=8.0,3. 7Hz,1H),3.78(s,3H),3.23(s,3H),3.04-2.94(m,4H),2.48-2.40(m,4H),2.20(s,3H ),2.00-1.86(m,2H),1.77-1.56(m,6H),0.76(t,J=7.5Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 480.3006.

[0324] Embodiment 31

[0325] The synthesis of (R)-8-cyclopentyl-7-ethyl-2-((3-fluoro-2-methoxy-5-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 31) is as follows:

[0326]

[0327] Referring to the preparation of compound 30, 4-bromo-2-fluoro-6-nitrophenol (raw material 1.8 g) was used instead of 4-bromo-2-nitrophenol (raw material 1 g) according to the same feed ratio to obtain the title compound 31 (502 mg, white solid, yield 46%); 1HNMR(600MHz,DMSO-d6)δ(ppm):7.83(s,1H),7.68(d,J=9.6Hz,1H),7.61(s,1H),6.43(d,J=14.4 Hz,1H),4.45(d,J=8.4Hz,1H),4.18(dd,J=7.9,3.5Hz,1H),3.77(s,3H),3.24(s,3H),3.10-3.02 (m,4H),2.41(dd,J=16.1,11.6Hz,4H),2.21(s,3H),1.92(dd,J=27.7,8.2Hz,2H),1.72(s,5H),1 .59(td,J=14.6,7.2Hz,1H),1.53(d,J=7.1Hz,2H),0.77(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) + , the measured value is 498.2981.

[0328] Embodiment 32

[0329] The synthesis of (R)-7-ethyl-2-((3-fluoro-2-methoxy-5-(4-methylpiperazin-1-yl)phenyl)amino)-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 32) is as follows:

[0330]

[0331] Referring to the preparation of compound 31, intermediate 13f was used to replace intermediate 1f according to the same feed ratio to obtain the title compound 32 (475 mg, light yellow solid, yield 52%); 1 H NMR (600MHz, DMSO-d6) δ (ppm): 7.83 (s, 2H), 6.40 (d, J = 14.4Hz, 1H), 4.74- 4.65(m,1H),4.27-4.22(m,1H),3.79(s,3H),3.24(s,3H),3.07(s,4H),2. 44(s,4H),2.21(s,3H),1.79-1.71(m,1H),1.63(dt,J=14.3,7.5Hz,1H),1 .30(dd,J=29.1,6.6Hz,6H),0.76(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) + , the measured value is 472.2836.

[0332] Embodiment 33

[0333] Synthesis of (R)-2-((3-chloro-2-methoxy-5-(4-methylpiperazin-1-yl)phenyl)amino)-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 33), the reaction scheme is as follows:

[0334]

[0335] With reference to the preparation of compound 30, 4-bromo-2-chloro-6-nitrophenol (raw material 2.2 g) was used instead of 4-bromo-2-nitrophenol (raw material 1 g) according to the same feed ratio to obtain the title compound 33 (463 mg, white solid, yield 49%); 1 HNMR (600MHz, CDCl3) δ (ppm): 8.11 (d, J = 2.8Hz, 1H), 7.68 (s, 1H), 7.36 (s, 1H), 6.49 (d, J=2.8Hz,1H),4.60(p,J=8.2Hz,1H),4.16(dd,J=8.2,3.8Hz,1H),3.85(s,3H),3.32(s, 3H),3.21-3.13(m,4H),2.60-2.52(m,4H),2.34(s,3H),2.10-1.97(m,2H),1.81(ddp,J =14.9,7.3,3.7Hz,3H),1.75-1.60(m,5H),0.88(t,J=7.5Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 514.2687.

[0336] Embodiment 34

[0337] The synthesis of (R)-2-((3-chloro-2-methoxy-5-(4-methylpiperazin-1-yl)phenyl)amino)-7-ethyl-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 34) is as follows:

[0338]

[0339] Referring to the preparation of compound 33, intermediate 13f was used to replace intermediate 1f according to the same feed ratio to obtain the title compound 34 (496 mg, white solid, yield 59%); 1H NMR (600MHz, DMSO-d6) δ (ppm): 7.97 (d, J = 2.7Hz, 1H), 7.83 (s, 1H), 7.60 (s, 1H), 6.54 (d, J = 2. 5Hz,1H),4.68(p,J=6.8Hz,1H),4.26(dd,J=7.9,3.3Hz,1H),3.73(s,3H),3.24(s,3H),3.12- 3.04(m,4H),2.47-2.39(m,4H),2.21(s,3H),1.76(ddd,J=14.0,7.4,3.4Hz,1H),1.62(dq,J= 14.8,7.4Hz,1H),1.29(dd,J=27.8,6.8Hz,6H),0.76(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) + , the measured value is 488.2536.

[0340] Embodiment 35

[0341] The synthesis of (R)-8-cyclopentyl-2-((5-((2-(dimethylamino)ethyl)(methyl)amino)-3-fluoro-2-methoxyphenyl)amino)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 35) is as follows:

[0342]

[0343] Referring to the preparation of compound 31, compound N1,N1,N2-trimethylethane-1,2-diamine was used to replace methylpiperazine according to the same feed ratio to obtain the title compound 35 (489 mg, off-white solid, yield 57%); 1 H NMR (600MHz, DMSO-d6) δ (ppm): 7.77 (s, 1H), 7.59-7.47 (m, 2H), 6.14 (dd, J = 14.8, 2.9Hz, 1H), 4 .43(p,J=8.3Hz,1H),4.18(dd,J=7.9,3.7Hz,1H),3.74(s,3H),2.87(s,3H),2.36(t,J=7.2Hz, 2H),2.17(s,6H),2.00-1.85(m,3H),1.72(dqd,J=15.0,8.7,7.3,3.2Hz,5H),1.61(dq,J=14.4 ,7.4Hz,1H),1.52(ddt,J=15.8,11.9,8.0Hz,2H),0.77(t,J=7.5Hz,3H); HRMS(ESI):m / z,(M+H) + , the measured value is 500.3137.

[0344] Embodiment 36

[0345] Synthesis of (R)-tert-butyl(1-(3-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-5-fluoro-4-methoxyphenyl)piperidin-4-yl)carbamate (Compound 36), the reaction scheme is as follows:

[0346]

[0347] Referring to the preparation of compound 31, the compound 4-tert-butyloxycarbonyl-aminopiperidine was used to replace methylpiperazine according to the same feed ratio to obtain the title compound 36 (526 mg, white solid, yield 52%); 1 H NMR(600MHz,DMSO-d6)δ(ppm):7.97(d,J=2.8Hz,1H),7.81(s,1H),7.37(s,1H),6.86(d,J=7.8Hz,1H) ,6.83(d,J=8.8Hz,1H),6.46(dd,J=8.8,2.9Hz,1H),4.46(t,J=7.9Hz,1H),4.15(dd,J=8.1,3.7Hz,1H) ,3.77(s,3H),3.43-3.38(m,2H),3.22(s,3H),2.60(t,J=11.8Hz,2H),1.99-1.85(m,3H),1.81-1.59( m,8H),1.51(ddt,J=35.9,12.2,6.2Hz,4H),1.37(s,9H),0.75(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) + , the measured value is 580.3602.

[0348] Embodiment 37

[0349] The synthesis of (R)-2-((5-(4-aminopiperidin-1-yl)-3-fluoro-2-methoxyphenyl)amino)-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 37) is as follows:

[0350]

[0351] Referring to the preparation of compound 31, the compound 4-aminopiperidine was used instead of methylpiperazine according to the same feed ratio to obtain the title compound 37 (563 mg, white solid, yield 58%); 1H NMR (600MHz, DMSO-d6) δ (ppm): 7.97 (d, J = 2.9 Hz, 1H), 7.81 (s, 1H), 7.37 (s, 1H), 6.83 (d, J = 8.9 Hz, 1H), 6.4 6(dd,J=8.8,2.9Hz,1H),4.48(q,J=8.3Hz,1H),4.16(dd,J=8.1,3.7Hz,1H),3.77(s,3H),3.41(d,J=12.1Hz ,2H),3.22(s,3H),2.70(d,J=11.5Hz,1H),2.63-2.56(m,2H),2.00-1.86(m,3H),1.82-1.76(m,3H),1.75- 1.65(m,5H),1.61-1.50(m,3H),1.40(q,J=11.7,11.0Hz,2H),0.75(t,J=7.5Hz,3H); HRMS(ESI):m / z,(M+H) + , the measured value is 480.3082.

[0352] Embodiment 38

[0353] The synthesis of (R)-8-cyclopentyl-7-ethyl-2-((5-(4-ethylpiperazin-1-yl)-3-fluoro-2-methoxyphenyl)amino)-5-methyl-7,8-dihydropteridin-6(5H)-one (Compound 38) is as follows:

[0354]

[0355] Referring to the preparation of compound 31, ethylpiperazine was used instead of methylpiperazine according to the same feed ratio to obtain the title compound 38 (502 mg, white solid, yield 46%); 1 H NMR (600MHz, DMSO-d6) δ (ppm): 7.86 (s, 1H), 7.73 (d, J=2.8Hz, 1H), 7.66 (s, 1H), 6.46 (dd, J= 14.3,2.9Hz,1H),4.49(p,J=8.2Hz,1H),4.21(dd,J=8.1,3.6Hz,1H),3.81(s,3H),3.39(s,1H ),3.09(t,J=4.9Hz,4H),2.54(s,1H),2.38(q,J=7.1Hz,2H),2.04-1.87(m,3H),1.82-1.70(m ,5H),1.69-1.50(m,4H),1.05(t,J=7.1Hz,3H),0.80(t,J=7.4Hz,3H); HRMS(ESI):m / z,(M+H) +, measured value 512.3143.

[0356] Embodiment 39

[0357] The synthesis of (R)-7-ethyl-2-((2-(2-hydroxyethoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-8-(4-piperidinyl)-7,8-dihydropteridin-6(5H)-one (Compound 39) is as follows:

[0358]

[0359] (1) Synthesis of Intermediate 2-(4-bromo-2-nitrophenoxy)ethane-1-ol (Intermediate 39a)

[0360] Step I: Weigh the raw material 4-bromo-2-nitrophenol (1.6 g, 7.34 mmol) into a thick-walled pressure bottle and dissolve it in a small amount of DMF solvent, add 2-bromoethanol (1.11 mL, 18.13 mmol) to the reaction system, then add N,N-diisopropylethylamine (5.75 mL, 33.03 mmol) dropwise to the reaction system, and stir the reaction at 120°C for 3 h. After the reaction is completed, extract with water and ethyl acetate (100 mL×3), combine the organic phases, dry over anhydrous sodium sulfate, concentrate under reduced pressure, and finally obtain intermediate 39a (1.6 g, orange-yellow solid, yield 85%) by column chromatography (petroleum ether: ethyl acetate = 6:1).

[0361] (2) Synthesis of Intermediate 2-(4-bromo-2-nitrophenoxy)ethyl acetate (Intermediate 39b)

[0362] Step II: 39a (1.6 g, 6.15 mmol) was dissolved in dichloromethane, and 4-dimethylaminopyridine (1.2 g, 9.84 mmol) and acetic anhydride (0.615 mL, 3.47 mmol) were added to the reaction system under ice bath conditions. After the system was stable, the ice bath was removed and the reaction was stirred at room temperature for 5 h. After the reaction was completed, the volatile solvent in the system was dried, and the mixture was extracted with water and ethyl acetate (100 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and finally column chromatography (petroleum ether: ethyl acetate = 8:1) was used to obtain intermediate 39b (1.7 g, yellow-green oil, yield 91%).

[0363] (3) Synthesis of Intermediate 2-(4-(4-methylpiperazin-1-yl)-2-nitrophenoxy)ethyl acetate (Intermediate 39c)

[0364] Step III: 39b (1.7 g, 5.59 mmol) was dissolved in 10 mL of anhydrous 1,4-dioxane in an eggplant-shaped bottle. 1-Methylpiperazine (0.63 mL, 5.65 mmol), cesium carbonate (2.73 g, 8.385 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.65 g, 1.12 mmol) were added to the eggplant-shaped bottle in sequence. A balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle. The nitrogen was pumped out several times with a vacuum pump until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.51 g, 0.559 mmol) was quickly added. The nitrogen was repeatedly pumped out with a vacuum pump for about one hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 110°C for 18 h. After the reaction solution was cooled to room temperature, it was filtered and washed with ethyl acetate. The filtrate was collected and extracted with water and ethyl acetate (100 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 39c (1.46 g, brown oil, yield 81%) was obtained by column chromatography (ethyl acetate: methanol = 10:1).

[0365] (4) Synthesis of Intermediate 2-(2-amino-4-(4-methylpiperazin-1-yl)phenoxy)ethyl acetate (Intermediate 39d)

[0366] Step IV: 39c (1.46 g, 4.98 mmol) was dissolved in a mixture of ethanol and water (volume ratio of 2:1) as a solvent, ammonium chloride (0.8 g, 14.94 mmol) was added, and reduced iron powder (1.39 g, 24.9 mmol) was slowly added, and the mixture was refluxed and stirred at 60°C for 2 hours. After the reaction was completed, diatomaceous earth was used for suction filtration, and the filtrate was collected. The filtrate was extracted with ethyl acetate and water (100 mL×3), and the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Finally, intermediate 39d (0.73 g, brown-yellow solid, yield 55%) was obtained by column chromatography (ethyl acetate: methanol = 8:1).

[0367] (5) Synthesis of Intermediate (R)-4-(2-((2-acetoxyethoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-7-ethyl-5-methyl-6-oxo-6,7-dihydropteridin-8(5H)-yl)piperidine-1-carboxylic acid tert-butyl ester (Intermediate 39e)

[0368] Step V: 39d (0.73 g, 2.48 mmol) was dissolved in anhydrous 1,4-dioxane in an eggplant-shaped bottle, and intermediate (R)-4-(2-chloro-7-ethyl-5-methyl-6-oxo-6,7-dihydropteridin-8(5H)-yl)piperidine-1-carboxylic acid tert-butyl ester (intermediate 1f') (0.88 g, 2.98 mmol; the preparation method of intermediate 1f' refers to intermediate 1f, with N-tert-butyloxycarbonyl-4-piperidone replacing cyclopentanone), carbonyl ester and tert-butyl ester were added to the eggplant-shaped bottle in sequence. Cesium bis(diphenylphosphine) (1.21 g, 3.72 mmol) and 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthene (0.29 g, 0.5 mmol) were added to the eggplant-shaped bottle mouth, and a balloon filled with nitrogen was placed on the mouth of the eggplant-shaped bottle. The nitrogen was replaced by a vacuum pump several times until no bubbles emerged in the system. At this time, tri(dibenzylideneacetone)dipalladium (0.23 g, 0.25 mmol) was quickly added, and the nitrogen was repeatedly replaced by a vacuum pump for about an hour. Finally, the system was completely placed under nitrogen protection and reacted in an oil bath at 110°C for 16 hours. After the reaction solution was cooled to room temperature, the reaction solution was filtered and washed with ethyl acetate, the filtrate was collected, extracted with ethyl acetate and water, the organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and finally column chromatography (ethyl acetate: methanol = 10:1) was used to obtain intermediate 39e (0.9 g, brown solid, yield 61%).

[0369] (6) Synthesis of Intermediate (R)-2-(2-((7-ethyl-5-methyl-6-oxo-8-(piperidin-4-yl)-5,6,7,8-tetrahydropteridin-2-yl)amino)-4-(4-methylpiperazin-1-yl)phenoxy)ethyl acetate (Intermediate 39f)

[0370] Step VI: 39e (0.9 g, 1.59 mmol) was dissolved in 5 mL of dichloromethane, and 1 mL of trifluoroacetic acid was added dropwise to the reaction system under ice bath conditions. After the reaction system was stable, the ice bath was removed and the reaction was stirred at room temperature for 12 hours. After the reaction was completed, the volatile liquid was removed by vacuum concentration, and finally the intermediate 39f (0.65 g, light yellow solid, yield 67%) was obtained by column chromatography (ethyl acetate: methanol = 5:1).

[0371] (7) Synthesis of (R)-7-ethyl-2-((2-(2-hydroxyethoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-8-(4-piperidinyl)-7,8-dihydropteridin-6(5H)-one (Compound 53 or Compound 51g)

[0372] Step VII: 39f (0.65 g, 1.24 mmol) was dissolved in a mixture of methanol and water (volume ratio of 5:3) as a solvent, and then potassium carbonate (0.53 g, 3.72 mmol) was added to the reaction system and stirred at room temperature for 5 hours. After the reaction was completed, the volatile solvent was removed by concentration under reduced pressure, and compound 39 (0.61 g, white solid, yield 77%) was obtained by column chromatography (ethyl acetate: methanol = 4:1). HRMS (ESI): m / z, (M+H) + , measured value 525.3202.

[0373] Embodiment 40

[0374] Synthesis of (R)-7-ethyl-2-((5-(4-ethylpiperazin-1-yl)-2-(2-hydroxyethoxy)phenyl)amino)-5-methyl-8-(piperidin-4-yl)-7,8-dihydropteridin-6(5H)-one (Compound 40)

[0375]

[0376] Referring to the preparation of compound 39, ethylpiperazine was used instead of methylpiperazine according to the same feed ratio to obtain the title compound 40 (437 mg, yellow solid, yield 41%); 1 H NMR (600MHz, DMSO-d6) δ (ppm): 8.15 (s, 1H), 7.78 (d, J = 17.2Hz, 1H), 7.76 (s, 1H), 6.84 (s, 1H), 6.42 (s, 1H), 4. 21(s,1H),4.12(s,2H),3.93(s,3H),3.79(s,2H),3.70(s,1H),3.23(s,3H),3.16(s,3H),3.06-2.97(m,4H),2. 58(d,J=36.8Hz,2H),2.35(dd,J=14.3,7.1Hz,2H),2.25(s,1H),1.97(d,J=16.6Hz,1H),1.77(s,2H),1.65(d, J=25.5Hz,2H),1.40(dd,J=33.9,24.8Hz,2H),1.04-0.98(m,3H),0.74(t,J=7.0Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 539.2703.

[0377] Embodiment 41

[0378] Synthesis of (7R)-2-((3-chloro-2-(2-hydroxyethoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-7-ethyl-5-methyl-8-(pyrrolidin-3-yl)-7,8-dihydropteridin-6(5H)-one (Compound 41)

[0379]

[0380] With reference to the preparation of compound 39, 4-bromo-2-chloro-6-nitrophenol was used instead of 4-bromo-2-nitrophenol according to the same feed ratio, and 1-tert-butoxycarbonyl-3-pyrrolidone was used instead of the raw material N-tert-butoxycarbonyl-4-piperidone to obtain the title compound 41 (155 mg, white solid, yield 43%); 1 H NMR (600MHz, CDCl3) δ (ppm): 9.11 (s, 1H), 8.19 (d, J = 2.9Hz, 1H), 7.70 (s, 1H), 6.47 (d, J = 2.9Hz, 1H), 4.31 (ddd, J = 10.8, 5.1, 2 .1Hz,1H),4.16(dd,J=6.7,3.4Hz,1H),3.97(ddd,J=10.9,7.2,2.3Hz,1H),3.92-3.81(m,3H),3.61-3.52(m,2H),3.47(s,3H) ,3.31(s,3H),3.21(s,1H),3.00(td,J=10.2,7.3Hz,1H),2.66(p,J=8.5Hz,1H),2.57(t,J=5.0Hz,4H),2.34(s,3H),2.17(s,1 H),2.07-1.96(m,2H),1.78(dp,J=14.4,7.3Hz,1H),1.42(s,1H),1.32-1.21(m,1H),0.87-0.80(m,3H); HRMS(ESI):m / z,(M+H) + , measured value 545.2739.

[0381] Embodiment 42

[0382] Synthesis of (7R)-7-ethyl-2-((3-fluoro-2-(3-hydroxypropoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-8-(pyrrolidin-3-yl)-7,8-dihydropteridin-6(5H)-one (Compound 42)

[0383]

[0384] With reference to the preparation of compound 41, 4-bromo-2-fluoro-6-nitrophenol was used instead of 4-bromo-2-nitrophenol according to the same feed ratio, and 3-bromo-1-propanol was used instead of 2-bromoethanol to obtain the title compound 42 (178 mg, light yellow solid, yield 48%); 1 H NMR (600MHz, CDCl3) δ (ppm): 8.40 (s, 1H), 8.06 (dd, J = 2.9, 1.4Hz, 1H), 7.70 (s, 1H), 6.26 (dd, J = 13.7, 2.9Hz, 1H), 4.21 (ddd, J = 9. 5,5.9,3.8Hz,1H),4.16(dd,J=6.8,3.4Hz,1H),4.07(td,J=8.8,3.3Hz,1H),3.97-3.84(m,3H),3.47-3.43(m,1H),3.32(s,3H),3. 21-3.15(m,4H),3.01(ddd,J=10.8,8.7,6.9Hz,1H),2.67-2.61(m,1H),2.57(t,J=5.0Hz,3H),2.35(s,3H),2.17(s,2H),2.01(dd dd,J=21.1,17.4,14.1,9.4Hz,5H),1.80(dp,J=14.5,7.3Hz,2H),1.33-1.23(m,1H),0.85(t,J=7.5Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 543.3200.

[0385] Embodiment 43

[0386] Synthesis of (7R)-7-ethyl-2-((3-fluoro-2-((2S)-2-hydroxypropoxy)-5-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-8-(pyrrolidin-3-yl)-7,8-dihydropteridin-6(5H)-one (Compound 43)

[0387] Referring to the preparation of compound 42, the compound (S)-1-bromo-2-propanol was used to replace the raw material 2-bromoethanol according to the same feed ratio to obtain the title compound 43 (178 mg, light yellow solid, yield 48%); 1H NMR (600MHz, DMSO-d6) δ (ppm): 9.01-8.39 (m, 1H), 8.19-7.90 (m, 1H), 7.83 (d, J = 18.5Hz, 1H), 6.38-6.29(m,1H),4.28(d,J=26.9Hz,2H),4.06-3.81(m,2H),3.66-3.47(m,2H),3.26-3.14(m ,5H),3.07(dt,J=6.5,3.5Hz,5H),2.43(t,J=5.0Hz,4H),2.20(d,J=17.6Hz,4H),1.61(d,J=2 .4Hz,2H),1.28-1.16(m,4H),1.14-1.07(m,2H),0.74(q,J=7.3Hz,3H); HRMS(ESI):m / z,(M+H) + , measured value 543.3197.

[0388] Biological evaluation test case

[0389] Test Example 1: Determination of the inhibitory activity of the compounds of the present application on Plks kinase

[0390] Transphosphorylation assays were used to determine the inhibitory activity of putative kinase inhibitors and the potency of selected compounds. 33 In the presence of ATP tracer P-γ-ATP, specific peptide or protein substrates are transphosphorylated by their specific serine-threonine or tyrosine kinases in the presence of their own optimal buffer and cofactors.

[0391] The principle of the activity test method is as follows: This experiment uses the transphosphorylation assay to determine the inhibitory activity of Plk1 kinase inhibitors. The specific working principle is to 33 The ATP labeled with P-γ-ATP transphosphorylates a specific protein substrate under the action of specific Plk1 kinase. When the phosphorylation reaction is completed, the different fluorescence absorption intensities of unlabeled ATP and radioactive ATP are detected by an enzyme reader to evaluate their activity.

[0392] The specific operations are:

[0393] (1) Prepare hPlk1, hPlk2 and hPlk3 kinase buffers by adding hPlk1, hPlk2 and hPlk3 to 8 mM MOPS pH 7.0, 0.2 mM EDTA, 20 mM DTT, 1.25 mg / mL casein, 10 mM magnesium acetate and [γ- 33 P-ATP] and diluted in a buffer solution for later use;

[0394] (2) All compounds (0.5 mg) were dissolved and diluted with DMSO to 9 concentration gradients, namely 0.001 μM, 0.003 μM, 0.01 μM, 0.03 μM, 0.1 μM, 0.3 μM, 1 μM, 3 μM, and 10 μM;

[0395] (3) The prepared compound solution was added to a 96-well plate and replicated once, and then the previously prepared kinase buffer was added. The buffer was used as a blank group. The reaction was marked by the addition of the MgATP mixture. After incubation at room temperature for about 40 minutes, 5 μL of 3% phosphoric acid solution was added to terminate the reaction. Then 10 μL of the reaction solution was dropped onto a P30 filter pad, washed three times with 75 mM phosphoric acid within five minutes, and washed once with methanol before drying and scintillation counting. The fluorescence intensity absorption value was detected by an enzyme reader, and the inhibition rate was calculated by scintillation counting;

[0396] (4) Draw the inhibition curve and calculate the IC by analyzing the inhibition curve. 50 The results are shown in Table 1.

[0397] Table 1: IC values ​​of small molecule inhibitors of this application on human hPlks enzyme 50 (nM) value

[0398]

[0399]

[0400]

[0401] IC of the compounds of the present application for Plk1 kinase 50 The values ​​were between 10 and 200 nM, and most of them were between 10 and 50 nM. The inhibitory activity of some compounds on P1k1 exceeded that of the positive control BI 2536. The selectivity within the P1k family of all compounds was greatly improved. For example, the selectivity of the positive compound BI 2536 for Plk2 and Plk3 was 2.7 and 1.8, respectively, while the selectivity of the compounds of the present application for Plk2 and Plk3 was mostly greater than 100, and several compounds exceeded 300.

[0402] Test Example 2: Determination of the inhibitory activity of the compounds of the present application on various cancer cell lines in vitro

[0403] According to the results of the kinase test, the compounds of the present application were selectively subjected to CCK-8 cell experiments in 9 cell lines, including the following human colorectal adenocarcinoma cell lines SW620, SW480, human pancreatic cancer cell line MIA-PACA2, human non-small cell lung cancer cell line A549, human non-small cell lung cancer cell line H460, human lung adenocarcinoma cell line PC-9, human pancreatic cancer cell line PANC-1, and SW1990.

[0404] First, the tumor cells were cultured in culture medium until the logarithmic growth phase, and then digested with 0.25% trypsin to prepare a single cell suspension. The cells were diluted to 2X10 4 / mL, the obtained cell suspension was inoculated into the wells of a 96-well plate and cultured in an incubator at 37°C and 5% CO2 for 24 h. The compound to be tested and the positive control BI 2536 were prepared with DMSO at a concentration of 1.00×10 -5 mol / , 3.33×10 -6 mo1 / L、1.11×10 -6 mol / L、3.7×10 -7 mol / L、1.23×10 -7 mol / L、4.12×10 -8 mol / L、1.37×10 -8 mol / L、4.57×10 -9 mol / L、1.52×10 -9 mol / L、5.08×10 -1 10 solutions with different concentration gradients of 100 μmol / L were added to a 96-well plate and cultured for 48 hours. Then, 40 μL of 2.5 mg / mL CCK-8 detection reagent prepared with PBS was added to each well. After 4 hours, the supernatant in the well was discarded, 150 μL / well DMSO was added to dissolve, and the crystals were gently shaken until they were completely dissolved. The absorbance value (OD value) at a wavelength of 450 nm was detected by an enzyme marker. The dose-response curve was obtained by plotting the different concentrations of the drug and the inhibition rate of the cells, from which the half-maximal inhibition concentration of the drug was calculated. The experiment was repeated in three groups. The results are shown in Table 2.

[0405] Table 2: Cellular activities of exemplary small molecule inhibitors in this application against three different cancer cell lines

[0406]

[0407]

[0408] Conclusion: The exemplified compounds in this application all showed good activity in inhibiting the growth of cancer cells against H460 cancer cell lines.

[0409] Solubility Evaluation Test Example

[0410] The principle of the solubility test method is as follows: weigh 5 mg of the test compound, add 2 μL of DMSO solvent to the compound to promote the full dissolution of the compound, and then add 100 μL of PBS buffer solution (pH = 7.4) to the test compound. After incubation in a constant temperature incubator for 12 hours, separate the precipitate by centrifuge. The solubility of the test compound is determined by the ultraviolet absorbance of each centrifuged filtrate. The water solubility test results of some compounds predicted and tested are shown in Table 3.

[0411] Table 3: Water solubility test results of exemplary small molecule inhibitors in this application

[0412]

[0413] Conclusion: The exemplary compounds in this application all showed good water solubility, and their solubility in water was significantly better than that of the positive compound BI 2536. BI 2536 is administered by intravenous injection. Since the water solubility and other physical and chemical properties of the exemplary compounds in this application have been greatly improved, it is possible to develop oral dosage forms with better compliance, such as tablets and capsules.

[0414] Test Example 4: Study on the therapeutic effect of compound 7 in a non-small cell lung cancer (A549) transplanted tumor mouse model

[0415] 18-20g BALB / c nude mice were randomly divided into 4 groups, 4 mice in each group, and kept in an SPF animal culture room at a constant temperature of 23°C. A549 cells were expanded and cultured. After digestion, centrifugation and washing, 2×105 A549 cells were evenly dispersed in a 200μL (100μL matrix gel and 100μL DMEM culture medium) suspension. 200μL of cell suspension was subcutaneously injected into the right armpit of each nude mouse with a 1mL medical syringe. After about two weeks of feeding, the volume of the transplanted tumor in the armpit was measured with a vernier caliper, and oral administration was started when the tumor volume reached 100mm. Grouping method: divided into a blank control group (Vehicle), a compound 7 (10mg / kg) group, and a BI2536 (10mg / kg) group. The mice in the control group were gavaged with 30% PEG-400 aqueous solution once and gavage twice a week; the compound 7 (10 mg / kg) group was gavage twice a week; the BI2536 (10 mg / kg) group was intraperitoneally injected twice a week; the administration was continued for 21 days. The tumor volume and nude mouse body weight were measured every two days. After 21 days of administration, the animals were anesthetized with 10% chloral hydrate, and the animals were killed by dislocation of the neck after sampling. The nude mice were killed, the tumors were removed, the tumor weight was weighed, and then fixed with 4% paraformaldehyde.

[0416] Statistics and processing of data: The results were described by mean standard deviation (X±SD), and individual data were directly listed. When the sample size was less than 3, no statistical comparison was performed on the data of this group. The quantitative indicators were first tested for variance homogeneity using the LEVENE test. When the variance was homogeneous (P>0.05), one-way analysis of variance (ANOVA) was used for statistical testing; when the variance was unequal (P≤0.05), the Kruskal-Wallis H rank sum test (KW method) was used for statistical analysis. When the one-way ANOVA showed that the difference was statistically significant (P≤0.05), the Dunnett's t test (Dunnett method) was used to compare the differences between the groups; when the one-way ANOVA showed that the difference was not statistically significant (P>0.05), the statistical analysis ended. When the Kruskal-Wallis H rank sum test showed a statistically significant difference (P ≤ 0.05), the Mann-Whitney U test (MW method) was used to compare the differences between the groups; when the Kruskal-Wallis H rank sum test showed no statistically significant difference (P> 0.05), the statistical analysis was terminated. All tests were two-sided tests with a p value of 0.05. All analyses were performed by gender. GraphPad Prism version 8 data acquisition system was used for statistical analysis.

[0417] Test Example 5: Study on the therapeutic effect of compound 28 on a non-small cell lung cancer (K562) transplanted tumor mouse model

[0418] 18-20 g BALB / c nude mice were randomly divided into 4 groups, 4 mice in each group, and kept in an SPF animal culture room at a constant temperature of 23°C. K562 cells were expanded and cultured, and 2×10 5 K562 cells were evenly dispersed in a 200 μL suspension (100 μL matrix gel and 100 μL DMEM culture medium). 200 μL of cell suspension was subcutaneously injected into the right armpit of each nude mouse with a 1 mL medical syringe. After about two weeks of feeding, the volume of the transplanted tumor in the armpit was measured with a vernier caliper, and oral administration began when the tumor volume reached 100 mm. Grouping method: divided into blank control group (Vehicle), compound 28 (10 mg / kg) group, compound 28 (20 mg / kg) group, and BI2536 (10 mg / kg) group. The control group mice were gavaged with 30% PEG-400 aqueous solution once, and gavage was administered twice a week; the compound 28 administration group was gavaged twice a week; the BI2536 (10 mg / kg) group was intraperitoneally injected twice a week; and the administration was continued for 11 days. The tumor volume and nude mouse weight were measured every two days. After 21 days of administration, the animals were anesthetized with 10% chloral hydrate and killed by dislocation of the neck after sampling. The nude mice were sacrificed, the tumors were removed, weighed, and then fixed with 4% paraformaldehyde.

[0419] Statistics and processing of data: The results were described by mean standard deviation (X±SD), and individual data were directly listed. When the sample size was less than 3, no statistical comparison was performed on the data of this group. The quantitative indicators were first tested for variance homogeneity using the LEVENE test. When the variance was homogeneous (P>0.05), one-way analysis of variance (ANOVA) was used for statistical testing; when the variance was unequal (P≤0.05), the Kruskal-Wallis H rank sum test (KW method) was used for statistical analysis. When the one-way ANOVA showed that the difference was statistically significant (P≤0.05), the Dunnett's t test (Dunnett method) was used to compare the differences between the groups; when the one-way ANOVA showed that the difference was not statistically significant (P>0.05), the statistical analysis ended. When the Kruskal-Wallis H rank sum test showed a statistically significant difference (P ≤ 0.05), the Mann-Whitney U test (MW method) was used to compare the differences between the groups; when the Kruskal-Wallis H rank sum test showed no statistically significant difference (P> 0.05), the statistical analysis was terminated. All tests were two-sided tests with a p value of 0.05. All analyses were performed by gender. GraphPad Prism version 8 data acquisition system was used for statistical analysis.

[0420] Test Example 6: Metabolic properties of compounds 7 and 28 in mice

[0421] The metabolic properties of the compounds in mice were detected by ICR mice. ICR male mice weighing 20-22g were selected, with 3 mice in each group. Compounds 7 and 28 were administered by gavage (10 mg / kg) and tail vein injection (1 mg / kg), respectively. The compounds were dissolved in 5% DMSO, 10% Solutol HS-15, and 85% hydroxypropyl-β-cyclodextrin 10.5% solution. Then blood was collected at 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 hours, 20 μL each time, and 200 μL 0.1% FA ACN:MeOH was added; after mixing for 10 minutes, centrifuged at 14000 rpm for 10 minutes; 100 μL of the supernatant was diluted with 200 μL 0.1% FA 25% MeOH; after mixing evenly, 0.3 μL was taken for LC-MS / MS detection. Liquid phase conditions: ACQUITY-BEH-C18 column (2.1*50 mm, 1.7 μm), mobile phase A: acetonitrile / water 95:5 (v / v) containing 0.1% FA; mobile phase B: water / acetonitrile 95:5 (v / v) containing 0.1% FA, 2 mM ammonium acetate; mass spectrometry conditions: GS1:40; GS2:70; evaporator temperature: 400°C; ionization spray voltage: 2000 V. The blood drug concentration curve was drawn based on the data, and the pharmacokinetic parameters were calculated.

[0422]

[0423] Although the embodiments of the present application have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present application, and that the scope of the present application is defined by the appended claims and their equivalents.

Claims

1. A novel tetrahydropteridine derivative, as shown in the general formula (I), or its tautomers, geometric isomers, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts thereof: R1 and R2 are each independently selected from hydrogen and C1-C6 alkyl; R3 is hydrogen, C1-C 10 Alkyl, C6-C 12 Aryl, C3-C 10 Cycloalkyl or C2-C 12 Heterocycloalkyl; R4 is hydrogen or C1-C6 alkyl; R5 is halogen, unsubstituted C1-C6 alkoxy or C1-C6 alkoxy substituted by hydroxy; X is hydrogen or halogen; L1 and L2 are each independently selected from a single bond (or absent) and C1-C4 alkylene optionally substituted by a group of Group A; R 10 is hydrogen or a C1-C4 alkyl group optionally substituted by a group of Group A, or R 10 and R7 and together with the groups to which they are attached form a C2-C 11 Azacycloalkyl, or R 10 and R9 and together with the groups to which they are attached form a C2-C 11 Azacycloalkyl; R6 and R7 are each independently selected from hydrogen, halogen, C1-C4 alkyl optionally substituted by a group of Group A, nitro, hydroxyl, and C1-C4 alkoxy optionally substituted by a group of Group A; R8 and R9 are each independently selected from hydrogen, C1-C6 alkyl optionally substituted by a group of Group A, and C1-C4 alkanoyl optionally substituted by a group of Group A; Group A groups are hydroxyl, nitro, halogen, C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, C6-C 12 Aryl-substituted C1-C6 alkyl, halogenated C1-C6 alkoxy or C6-C 12 Aryl.

2. The derivative according to claim 1, or its tautomer, geometric isomer, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen and R2 is C1-C6 alkyl, preferably, R1 is hydrogen and R2 is ethyl, and the carbon atom to which R1 and R2 are attached is in R configuration.

3. The derivative according to claim 1, or its tautomer, geometric isomer, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein: R3 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl or piperidinyl, preferably, R3 is isopropyl, cyclopentyl, pyrrolidinyl or piperidinyl.

4. The derivative according to claim 1, or its tautomer, geometric isomer, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein: R4 is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl or tert-butyl, preferably, R4 is methyl.

5. The derivative according to claim 1, or its tautomer, geometric isomer, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein: R5 is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, hydroxymethoxy, hydroxyethoxy, hydroxy-n-propoxy, hydroxyisopropoxy, hydroxy-n-butoxy, hydroxyisobutoxy, hydroxy-sec-butoxy or hydroxy-tert-butoxy, preferably, R5 is methoxy, 2-hydroxyethoxy, 3-hydroxypropoxy or 2-hydroxypropoxy.

6. The derivative according to any one of claims 1 to 5, or its tautomer, geometric isomer, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein: X is hydrogen, chlorine, bromine, fluorine or iodine, preferably, X is hydrogen, chlorine or fluorine.

7. The derivative according to any one of claims 1 to 6, or its tautomer, geometric isomer, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein: Medium R 10 is hydrogen, L1 is a single bond, -CH2- or -CH2-CH2-; L2 is a single bond, -CH2- or -CH2-CH2-; R6 and R7 are both hydrogen; R8 and R9 are each independently selected from hydrogen, C1-C6 alkyl optionally substituted by a group of Group A, and C1-C4 alkanoyl optionally substituted by a group of Group A; preferably, R 10 is hydrogen, L1 is -CH2-; L2 is -CH2-; R6 and R7 are both hydrogen; R8 is hydrogen, and R9 is methyl or ethyl; More preferably, R 10 is hydrogen, L1 is -CH2-; L2 is -CH2-; R6 and R7 are both hydrogen; R8 is hydrogen, and R9 is ethyl.

8. The derivative according to any one of claims 1 to 6, or its tautomer, geometric isomer, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein: It is R8(R9)N-pyrrolidinyl optionally substituted by a group of Group A or R8(R9)N-piperidinyl optionally substituted by a group of Group A, and R8 and R9 are each independently selected from hydrogen, C1-C6 alkyl optionally substituted by a group of Group A, and C1-C4 alkanoyl optionally substituted by a group of Group A; preferably, it is R8(R9)N-pyrrolidinyl or R8(R9)N-piperidinyl, and R8 and R9 are each independently selected from hydrogen and tert-butoxycarbonyl; more preferably, it is 4-aminopiperidine or 4-tert-butoxycarbonyl-aminopiperidine.

9. The derivative according to any one of claims 1 to 6, or its tautomer, geometric isomer, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein: It is 4-R8-piperazinyl optionally substituted by a group of Group A, R8 is hydrogen, C1-C6 alkyl optionally substituted by a group of Group A, or C1-C4 alkanoyl optionally substituted by a group of Group A; preferably, it is 4-R8-piperazinyl, R8 is hydrogen, methyl, ethyl or tert-butoxycarbonyl.

10. A compound, or a pharmaceutically acceptable salt thereof, selected from one of the following structures:

11. A method for preparing the derivative according to claim 1, or its tautomer, geometric isomer, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, the preparation method comprising: Formula (II) and formula (III) are coupled to obtain a novel tetrahydropteridine derivative as shown in general formula (I), wherein the definitions of the substituents in formula (II) and formula (III) are the same as those in formula (I).

12. A pharmaceutical composition comprising a therapeutically effective amount of a derivative according to any one of claims 1 to 10, or a tautomer, geometric isomer, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier excipient or diluent.

13. Use of the derivative according to any one of claims 1 to 10, or its tautomer, geometric isomer, enantiomer, diastereomer, or a mixture thereof or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 12 as a selective inhibitor of Plk1 kinase, preferably, in the preparation of a medicament for treating or preventing diseases caused by excessive proliferation of malignant tumor cells.

14. The use according to claim 13, wherein The diseases caused by excessive proliferation of malignant tumor cells include: colorectal adenocarcinoma, pancreatic cancer, non-small cell lung cancer, small cell lung cancer, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, prostate cancer, epidermal cell cancer, esophageal cancer, thyroid cancer, acute leukemia, chronic myeloid leukemia, digestive tract cancer, liver cancer, lymphoma, myeloma, head and neck tumors, etc.